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EXPRESSION OF KI67, P53 AND MUC1 IN RENAL CELL 
CARCINOMA IN CORRELATION WITH NUCLEAR GRADE 
ABSTRACT 
AIMS AND OBJECTIVES: 
    Renal cell carcinoma comprises 2-3% of adult malignancies. It has 
been very challenging to predict the prognosis of each of the patients with RCC; 
when assessing cancer prognosis, classic prognostic factors, staging and grading 
were also not always accurate in prediction. In different studies, Ki67, p53 and  
MUC1 have been considered as a good predictive marker for RCC aggression, 
prognosis and survival outcome of patients. In this study, an attempt has been 
made to compare the expression of Ki67, p53 and MUC1 markers with nuclear 
grade and other clinicopathological parameters.  
MATERIALS AND METHODS: 
The clinical and pathological findings of Renal cell carcinoma cases were 
retrieved from the pathology records from august 2011 to august 2014 in Rajiv 
Gandhi Government General Hospital, Chennai. Totally 52 cases of renal cell 
carcinoma was studied and of this, 40 cases were randomly selected and 
immunohistochemistry was done using Ki67, p53, and MUC1. 
  
RESULTS: 
         Among 52 cases studied, 36 were clear cell RCC, 8 were papillary RCC, 2 
were Chromophobe RCC, 6 were unclassified RCC. Most common nuclear 
grade was Furhman nuclear grade 3. 
 There was statistically significant association of Ki67 expression with nuclear 
grade and stage at presentation. Association between p53 and histological type 
was found to be significant. There is significant association of MUC1 
expression with nuclear grade and stage.  
CONCLUSION: 
            The combined detection of Ki67, p53 and MUC1 expressions, which are 
superior to single marker along with nuclear grade and stage, could be used to 
significantly improve the accuracy in predicting the prognosis of  RCC patients. 
KEY WORDS: 
          Renal cell carcinoma, nuclear grade, immunohistochemistry. 
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INTRODUCTION 
 
 Renal cell carcinoma comprises 2-3% of adult malignancies.(1) The 
most lethal urological malignancy is Renal cell carcinoma  and 
annually100,000 deaths worldwide were caused by it.(2) Since 1970’s, 
annualy there has been 2-4% rise  in incidence of RCC. The use of 
radiological imaging can find  presymptomatic RCC lesion which has 
been one of the reason for this recent rise  in incidence and another reason 
being the increased prevalence of smoking and obesity which are some of 
the important predisposing risk factors. Among patients evaluated for  
non-specific musculoskeletal and abdominal complaints, CT scan 
incidentally picked up approximately approximately 30-60% of patients 
having RCC.(3) RCC has been found in about 20–30% of patients after the 
occurrence of metastasis.(4,5) 
 
 Prognosis of renal cell carcinoma  is dependent on different factors 
like early weight and dimensions,  tumor stage and tumor cell 
morphology. Different grading systems are used for RCC.(6) Nuclear 
grading was found to correlate with patients survival.(7) Cellular 
proliferation rate , apoptosis metastatic  spread are another predictive 
variable for biologic aggression of RCC and therefore  affects 
prognosis.(6,8) 
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 Cellular proliferation rate  in RCC could be evaluated by studying 
Ki67 antigen expression and PcNA (proliferate cell nuclear antigen). 
Apoptosis degree in tumor can be measured by detecting mutant P53 
antigen.(6) MUC1 have a role in cellular polarity, cell adhesion, and signal 
transduction. In many epithelial cancers, there is a loss of polarized 
cellular expression and there is diffuse circumferential distribution. In 
carcinomatous cells ,these variations of expression are suspected to 
participate in the metastatic dissemination. (8) 
 
 It has been very challenging to predict the prognosis of each of the 
patients with RCC; when assessing cancer prognosis,   classic prognostic 
factors, staging and grading were also not always accurate in 
prediction.(5,9) Treatment of metastatic RCC has dramatically changed  in 
the last decade and leads to revival of new hope to patients affected by 
this malignancy and changed the traditional thinking of grave prognosis 
in terms of survival among patients diagnosed in advanced stages. So 
there has been a definite need for better tools  in predicting the clinical 
course of RCC  in this era of evergrowing novel molecular targeted 
therapies. 
 
 For  proper counselling of the patient  and  for proper  planning and 
individualizing patient treatment, accurate prognostication is  of utmost 
importance.(9) In different studies, Ki67, P53 and  MUC1 have been 
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considered as a good predictive marker for RCC aggression, prognosis 
and survival outcome of patients.(6,8)  
 
 The  purpose of this study was to access the expression of P53, Ki 
67, MUC1 in different types of renal cell carcinoma. The  expression  of 
these apoptotic, proliferative and metastatic marker was compared with 
the nuclear grading. Increasing severity and reactivity rate to these 
markers have been always followed by poor prognosis. 
 
  
AIMS  
AND  
OBJECTIVES 
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AIMS AND OBJECTIVES 
 
 To study the incidence and distribution of renal cell carcinoma  in 
patients who attended Rajiv Gandhi Government General Hospital 
from august 2011 to august 2014. 
 To study the clinicopathological features of renal cell carcinoma 
 To determine the expression of ki67, P53 and MUC1 by 
immunohistochemistry  in renal cell carcinoma. 
 To study the correlation between ki67, P53 andMUC1 with nuclear 
grade 
 
  
 
REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
 
EPIDEMIOLOGY 
 Kidney tumor constitutes approximately 3% of all malignant 
tumors in adults.(2) Renal cell cancer (RCC) comprises 90% of all 
malignancies of the kidney that occur in adults in both sexes. Among 
males it ranks 6th  in industrialized areas and 16th  in less developed area. 
In women it ranks 12th in developed and 17th in developing countries 
respectively.(10) RCC is a heterogeneous group of hereditary or sporadic 
malignancies that arise from renal cells. Its frequency is next to prostate 
and bladder cancer, but it is the most lethal of these malignancies.  
 
 The incidence of RCC has been reported to be relatively high in 
North America, Scandinavia and Australia compared to other countries.(2) 
In several Eastern and Western European countries and also in parts of 
Italy, North America and  Australia/New Zealand, incidence of RCC  has 
been generally the highest. The lowest incidence of RCC are found in 
Africa and Asia.(11) The incidence of this malignancy  has been increasing 
steadily at the rate of 2-3%per year.(12,13) Around 20-30% of the RCC  has 
been estimated to present in the stage of metastasis.(14,15) It is also a well 
known fact that advanced overall TNM stage tumours can have low T-
stage and they account for 25% of widely metastatic disease in few 
studies.(16) 
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AGE AND GENDER 
 Most commonly RCC occurs in the fourth to sixth decades of life, 
but both sporadic and in particular hereditary tumors have been reported 
in children.(17) Among both low and high risk countries, men were 
affected two to three times more commonly than  women.(18) 
 
RISK FACTORS 
 Most common cause of renal malignancy is tobacco smoking and 
in males, around 39% of all cases were caused by it.(19) Carcinogenic 
arsenic compounds in industrial processes or  drinking water increases the 
risk  by 30%.(20) Asbestos, cadmium, some organic solvents, pesticides 
and fungal toxins are addressed as possible carcinogens for the kidney but 
definitive evidence has not been established.(20,21)  
 
 Estrogens could be a risk factor for RCC in obese and overweight 
individuals. Several epidemiological studies  conducted in many different 
populations have found out  that the incidence of renal malignancy 
increases steadily with increase  in  body mass index (BMI).(22) Cho et al 
concluded in his prospective study that long term use of  nonsteroidal 
anti-inflammatory drugs may raise the incidence of renal cancer.(23) In 
people suffering from chronic hypertension, the incidence of RCC is 
significantly increased that is independent of tobacco smoking and 
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obesity.(24,25,26) RCC has been established with exposure to analgesics 
containing phenacetin.(20) 
 
CLINICAL PRESENTATION 
 According to the mode of detection RCCs are classified in two 
groups: symptomatic and incidental. The classic triad of  presentation 
with hematuria, abdominal pain and flank mass is encountered less 
frequently than previously and is indicative of advanced disease. The 
typical tumor presents with lack of warning signs in early stage and can 
be clinically occult during majority of its time course. Majority of the 
RCCs are now incidentally found during investigations  for complaints 
which are not expected in the renal cancer and due to the increasing use 
of imaging investigations  such as ultrasonography(USG), computed 
tomography (CT)scan and magnetic resonance imaging (MRI) study.(27,28) 
 
 RCC remains a challenging malignancy due to its paraneoplastic 
manifestations such as hypercalcaemia, erythrocytosis, increased 
erythrocyte sedimentation rate, and non-metastatic  hepatic dysfunction.  
 
Most common presentations are 
 Abdominal pain (40%) 
 hematuria (40%) 
 Abdominal mass (25%) 
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 loss of weight (33%) 
 fever (20%) 
 Systemic hypertension (20%) 
 
 Fatigue and varicocele, left side is usually affected, because of 
testicular vein` obstruction  by the tumour extension(2% of males). The 
contribution of erythrocyte sedimentation rate (ESR) in prediction of 
prognosis has been a matter of debate in several studies.(29,30) However, in 
the recent studies of Kawai et al.(31) And Magera et al(32) preoperative 
ESR has been identified as a significant independent prognostic factor in 
patients with localized Clear Cell RCC. ESR is also found to be an 
independent prognostic factor in patients with metastatic RCC treated 
with or without cytoreductive radical nephrectomy.(33) 
 
GENETICS  
 The Von Hippel-Lindau gene (VHL) is mutated or inactivated in 
most sporadic clear cell carcinomas which is an early event in the 
carcinogenesis of the tumor. The normal function of VHL includes 
regulation of oxygen dependent expression of genes which will regulate 
cellular response to hypoxia. These include genes associated with 
erythropoiesis, angiogenesis  and resistance to hypoxia. Von Hippel- 
Lindau protein regulate ubiquitn –mediated destruction of hypoxia 
inducible factors. In the absence of VHLp there is high level of HIF 
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which induces production of endothelin-1, erythropoietin, vascular 
endothelial growth factor(VEGF), ceruloplasmin, transforming growth 
factor, cyclin G2,  and these leads to tumor progression.(34) 
 
 Some  genetic syndromes are associated with  RCC. Von Hippel- 
Lindau disease is caused by mutation of Von Hippel-Lindau gene. This 
gene encodes a tumor suppressor protein. In 75% of sporadic clear cell 
carcinoma both gene copies are inactivated. Von Hippel-Lindau 
syndrome, or VHL disease, is syndrome with an autosomal dominant 
inheritance and it predisposes to a number of neoplasms, such as : 
RCC having features of clear cell histology 
 
 Pancreatic islet cell tumors and cysts  
 Pheochromocytoma 
 Hemangioblastomas 
 Retinal angiomas 
 Tumors of Endolymphatic sac  
 Cystadenomas of epididymis.(35) 
 
 When compared to sporadic tumors these tumors occur in younger 
age. They are also commonly bilateral and multicentric.(36) 
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Hereditary  leiomyomatosis and renal carcinoma 
 This is a syndrome with autosomal dominant inheritance and they 
occur due to germline mutation  in fumarate hydratase gene.(37) This 
inherited disease causes the affected individuals to have an increased 
incidence to suffer from  benign leiomyoma of skin and uterus and some 
of them develop RCC with type 2 features.(38) 
 
Hereditary papillary RCC 
 Hereditary papillary RCC is one of the genetic disorder with a 
pattern of autosomal dominant inheritance; multifocal and bilateral 
papillary RCC occur in the individuals with this syndrome. MET  
protooncogene have been mutated in 85% of families(39) 
 
TUBEROUS SCLEROSIS(TS) 
 This is a disorder of autosomal dominant pattern of inheritance . It 
is due to mutation in TSC1 or TSC2 gene. TSC1 is located on 
chromosome 9q34 .TSC2 is located on chromosome 6p13. Both of the 
genes encode tumor suppressor proteins. This disorder is characterised by 
multiple benign hamartoma in CNS, angiomyolipoma in kidney. There is 
an increase in incidence in RCC among these patients.(35) 
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BIRT-HOGG-DUBE SYNDROME 
 This syndrome has an autosomal dominant pattern of inheritance. 
These patients have a high predisposition to be affected by benign 
neoplasms of the hair follicle, colonic polyps and pulmonary cysts.. There 
is an increased incidence of renal tumors.(40) 
 
HYPERPARATHYROIDISM (JAW TUMOUR SYNDROME) 
 Is a rare disorder with an autosomal dominant pattern of 
inheritance. Characterised by fibromas of the jaw, parathyroid adenoma 
and renal cell carcinoma.(41) 
 
DIAGNOSTIC METHODS 
 The renal mass has a wide range of differential diagnosis and 
includes pseudotumors, benign cysts, angiomyolipomas, vascular 
malformations, Wilm’s tumor, sarcoma, lymphoma, and metastases. 
However, percutaneous biopsy of a solid renal mass should not be 
undertaken, as more than 80% of such masses are RCC,(42) benign lesion 
and metastasis are rare . 
 
 As per the guidelines of National Comprehensive Cancer 
Network(NCCN) for the  RCC management, patients with known or 
suspected renal cell carcinoma should be further evaluated with routine 
laboratory studies (chemistry panel, complete blood count, urine analysis, 
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partial thromboplastin time and prothrombin time,), abdomen and pelvis 
computed tomography(CT) scan, X-ray of the chest,  and chest CT scan if 
the chest X-ray is abnormal or if there is extensive disease. Further 
studies such as a magnetic resonance imaging (MRI) of the brain and a 
bone scan should be undertaken only if clinically indicated.     
 
CT or MRI 
 Renal mass can be usefully characterised by the MRI or CT scan of 
the abdomen. In most patients, RCC be accurately diagnosed by these 
imaging studies. 
 
Information provided by abdominal CT are : 
 Morphology and function of the opposite kidney(43) 
 Anatomical extension of the primary tumour  
 Venous extension / invasion; 
 Regional lymph nodal involvement(enlargement) ; 
 Involvement of the adjacent adrenal glands and metastasis toliver 
  
 Contrast-enhanced biphasic abdominal CT angiography can be of 
useful in surgical cases to obtain accurate information about the vascular 
supply of the affected kidney  for on table clamping of segmental renal 
artery in cases planned for partial nephrectomy.(44,45) Biphasic MR 
angiography (MRA) can be done in the patient allergic to CT contrast but  
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MR angiography  is less accurate than CT angiography in accurate 
depiction of accessory renal vessels .(46) 
 
In patients with indeterminate CT results, MRI can give additional 
valuable information like : 
 show any enhancing areas in renal masses (including enhancing 
septations, wall and nodular components in complex cystic 
masses).(47) 
 more accurately  establish the anatomical extensions in case of 
locally advanced malignancy. 
  more accurately  establish venous extension of the tumour, if the 
involvement of an inferior vena cava(IVC) tumour thrombus is 
poorly depicted on CT scan.(48,49) 
 
MRI is also indicated in pregnant patients without renal failure.(50,51) 
 Among imaging for chest staging of metastatic RCC, most accurate 
investigation is the Chest CT. However, initially routine chest x-ray must 
be done for evaluation of large lung metastasis,  although this is less 
accurate in finding small metastasis, when comparing CT chest. At the 
time of diagnosis, most brain and bone metastases are symptomatic and it 
is not generally advised to do routine bone or brain imaging in the further 
investigation of the known RCC patient.(52,53) However, CT brain, MRI 
14 
 
brain or bone scan, may be carried out in patients presenting with related  
clinical  symptoms and signs.(54,55) 
 
RENAL TUMOUR BIOPSY  
 Image guided percutaneous biopsies of renal tumour are  of 
increasing  use : 
 
1. For histological diagnosis  in case of radiologically indeterminate 
renal mass lesions;  
2. For  categorising patients into surveillance group, in case of  small 
renal mass lesions; 
3. To get histological diagnosis before proceeding onto ablative 
treatment procedures;  
4. For deciding the most suitable means of targeted pharmacologic 
therapy for the stage of metastatic disease .(56,57,58) 
 
 Image guided percutaneous sampling in case of a renal mass can be 
done by means of trucut needle biopsy or fine needle aspiration. The 
main aim is to determine the nature of  malignancy, its exact histological 
type, and its exact nuclear  grade in view of its aggressiveness. 
 
 In view of the high accuracy in diagnosis of renal mass forming 
lesions by  abdominal imaging, biopsy of the renal mass forming lesions 
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before surgery is not always necessary, as in case of healthy individuals 
having  a long life expectancy. 
 
 Under local anesthesia, image guided percutaneous sampling in 
case of a renal mass can be done with the guidance of either ultrasound or 
CT.(59,60) Presently 18-gauge needles are considered ideal for trucut 
biopsies of the renal mass, as we can obtain sufficient amount of tissue 
and  can be done with low morbidity for diagnostic purpose in the 
majority of cases undergoing percutaneous biopsies. The complications 
which we most frequently encounter in percutaneous biopsy of a renal 
mass are spontaneously resolving hematoma (perinephric /subcapsular) 
and hematuria; its unusual (0-1.4%) to encounter clinically significant 
bleeding after biopsy and is usually self-limiting .(56,60) 
 
 On comparing to FNA,  trucut needle biopsies are usually more 
preferable in case of  solid renal masses, in view of its higher diagnostic 
yield and higher accuracy rate. For detailed histopatholigical analysis of 
the malignancy, it is necessary to obtain  at least two high quality biopsy 
cores (> 10 mm in length and non-fragmented) and to avoid sampling  
necrotic areas. In case of experienced biopsy centers, core needle biopsies 
of renal solid masses have obtain 78-97% diagnostic yield for the 
accurate diagnosis of the corresponding renal malignancies.  However, it 
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must be kept in mind that 2.5-22% of trucut needle biopsies are non 
diagnostic.(61,62) 
 
 Tumour grade assessment on core biopsy specimen is very 
challenging. The obtainable accuracy of Fuhrman grading on trucut 
needle biopsies is poor (43-75%); For cystic renal masses, diagnostic 
yield of needle core biopsies have been low and  usually biopsy must not 
be  done on these lesions unless accesseble solid areas   are present within 
the lesion (Bosniak IV cysts).(59,60) 
 
HISTOPATHOLOGICAL FEATURES  
 Renal cell carcinoma arises from the renal tubular epithelium. RCC 
is characterised by having unique morphological features and distinct 
genetic abnormalities.(63,64) The diagnosis of RCC is  based on unique 
histomorphological features. IHC and microRNA  techniques are used if 
histological findings are not concluvise in distinguishing the types of 
RCC.(63) The Fuhrman grading system is used for nuclear grading of 
RCC. This four-tiered system considers the nuclear features like size of 
the nucleus and nucleolus, shape of nucleus and nuclear content for 
nuclear grading.(65) 
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WHO CLASSIFICATION OF  RENAL CELL TUMOURS 
 Clear cell Renal cell carcinoma 
 Multilocular clear cell Renal cell carcinoma 
 Papillary Renal cell carcinoma 
 Chromophobe Renal cell carcinoma 
 Carcinoma of the collecting ducts of Bellini  
 Renal medullary carcinoma  
 Xp11 translocation carcinomas 
 Carcinoma associated with neuroblastoma 
 Mucinous tubular and spindle cell carcinoma 
 RCC, unclassified  
 Papillary adenoma  
 Oncocytoma 
 
CLEAR CELL RCC  
 This constitutes 70–80% of RCCs. The genetic abnormalities most 
frequently encountered in this type of RCC are von Hippel-Lindau (VHL) 
gene mutations , the chromosome 5q duplication  and chromosomal 
deletions at locations of 8p, 14q, 3p, 9p and 16q.(63,66) 
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Macroscopy 
 Clear cell renal cell carcinomas  are   randomly distributed cortical 
tumours. They are usually solitary and occur with equal frequency in 
either kidney. Less than 5 percent of cases are multicentric and 
bilateral.(67) Hereditary cancer syndromes like Von Hippel-Lindau disease 
are usually characterised by early age of onset, multicentricity and 
bilaterality. 
 
 Clear cell RCCs are  globular tumours .They  protrude from the 
renal cortex as a bosselated, rounded mass. The tumour and  adjacent 
kidney interface is usually well demarcated. The tumor is pseudocapsuled 
with a "pushing margin" . The tumor average size is 7 cm in diameter. In 
countries where radiologic imaging techniques are widely applied, 
detection of small tumor lesions is increasing. Size itself is not a 
determinant of malignancy though increasing size is associated with a 
higher frequency of metastases. All tumours of the kidney with clear cell 
type are considered as malignant tumours. Due to the rich lipid content of  
cells, neutral lipids, cholesterol and phospholipids, the clear cell renal cell 
carcinoma is typically golden yellow . Cysts, calcification, necrosis and 
haemorrhage are commonly present. Radiologically10to 15percent of 
tumours show calcification and ossification  within necrotic zones.(68,69) 
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Microscopy 
 On hemotoxylin and eosin (H&E) staining under light microscopy, 
cytoplasm of  Clear cell RCC appears more or less empty. This effect is 
due to the  intense glycogen and phospholipid accumulation in the 
cytoplasm which in turn is attributed to the increase in glucose-6-
phosphate levels induced by decreased gluconeogenesis and increased 
glycolysis.(70,71) In well differentiated tumours, the tumour cell nuclei are 
more condensed. The tumour cell nuclei exhibit more polymorphism and 
prominent nucleoli in less differentiated tumours.(72) Eosinophilic  or 
granular appearance of the cytoplasm is an another morphological variant 
of Clear cell RCC, which in turn is caused by the mitochondrial 
augmentation. 
 
 These tumors are characterised by variable architecture with acinar 
or tubular patterns. The stroma is poorly defined inspite of rich 
vasculature surrounding them. Occasionally, scattered bizarre nuclear 
forms are seen in otherwise typical tumors, a phenomenon similar to that 
more commonly seen in endocrine neoplasms and which should not be 
equated to sarcomatoid or anaplastic transformation.(73) The stroma of 
renal cell carcinoma is nondescript and, in general, not as abundant as in 
collecting duct carcinoma or transitional cell carcinoma. A lymphocytic 
infiltrate (mainly composed of T cells) of variable degree is present. 
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Cases have also been described in which the red blood cells in the stroma 
form clusters, resulting in a myospherulosis-like appearance.(74) 
 
Immunoprofile 
 Clear cell RCCs frequently react with antibodies to brush border 
antigens, low molecular weight cytokeratins(LMWCK), CK19, CK18, 
AE1, CK8,  vimentin and Cam 5.2. Detection of high molecular weight 
cytokeratins(HMWCK) are rare. The most of clear cell RCCs react 
positively for renal cell carcinoma marker epithelial membrane antigen 
and CD10. MUCΙ and MUC3 are consistently expressed .(75,76) 
 
MULTILOCULAR CYSTIC RCC 
 This tumor is characterised by numerous cysts in entirity. Within 
the septa of the cyst lies the small clear cell groups which is similar to 
clear cell carcinoma - grade Ι. There is male predominance. Mean age is 
51 years.(77) 
 
 Multilocular cystic renal cell carcinoma are well-circumscribed 
with serous or haemorrhagic fluid filled small and large cysts. A fibrous 
capsule is seen separating this lesion from the normal kidney. More than 
20% of tumors have  calcification in the septa .Usually a single epithelial 
cell layer lines the cysts or cyst may  lack  lining epithelium. The lining 
cells of the cyst may be plump or flat with a clear to pale cytoplasm. 
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Occasionally, the lining may be of cells of several layers or a few small 
papillae are seen.(78) The nuclei  are small and spherical with a  dense 
chromatin. Fibrous tissue forming the septa is  often densely collagenous. 
Within some of the septa, epithelial cell collections with a clear 
cytoplasm are seen. These epithelial cells usually resemble cells those 
lining the cysts and have small dark nuclei. These epithelial cells 
resemble histiocytes, or lymphocytes surrounded by retraction artefacts. 
The cells are strongly positive for cytokeratins(CK) and epithelial 
membrane antigen(EMA) . 
 
PAPILLARY RCC 
 Papillary RCC represents about 15% of all renal cell carcinomas. 
They arise in patients on chronic hemodialysis.(79) Some of the papillary 
renal cell carcinoma are hereditary, and these have been found to be 
associated with  the c-MET mutation.(80) It has a tendency towards 
multicentricity and bilaterality. This tumour has a distinct papillary 
growth pattern, with a solid pattern in undifferentiated areas. The 
papillary structure are lined by a single layer of neoplastic cells with a  
fibrovascular core containing foci of lipid-rich macrophages.(81,82) 
 
 This tumour can be divided into two types: type 1 papillary RCC, 
in which the papillae are lined by a single layer of cells; The cells have a 
pale scanty cytoplasm. Type 2 papillary RCC, in which the papillae are 
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lined by a pseudostratified epithelium. These cells are characterised by an 
abundant acidophilic cytoplasm.(83,84) Type 1 tumors that are accompanied 
by foamy macrophages and psammoma bodies and  are immunoreactive 
for keratin 7 and MUC1.(85,86) When compared to conventional renal cell 
carcinoma, this tumour  has a better prognosis.(87,81) 
 
 Papillary RCCs are characterised by the loss of Y chromosomes in 
males and trisomy of chromosomes 8p, 3q, 7, 16, 12, 20 and17.(63) 
Papillary renal cell carcinoma  can undergo anaplastic or sarcomatoid 
changes.(88) The presence of numerous foamy macrophages  and 
extensive tumour necrosis has been associated with a more favourable 
prognosis.(81,89) 
 
CHROMOPHOBE RCC 
 It comprises approximately 5% of  renal epithelial tumours. It has a  
lobulated surface with one or more solid tumour nodules. The cut surface 
of this tumour appears homogeneously orange; after formalin fixation, it 
turns beige or sandy.(90) 
 
 Microscopically, the characteristic feature is nesting (‘alveolar’) 
arrangement of  tumor cells.  Microcystic and adenomatous patterns of 
growth can also be seen sometimes.(91) The tumor cells have sharply 
defined borders. Cytoplasm is abundant and has a pale, acidophilic 
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quality. There is often a clear perinuclear region.(92) Pale cytoplasm  is 
due to the presence of numerous cytoplasmic vesicles.(93) With Hale 
colloidal iron technique, the microvesicles are stained blue.(94) 
Calcification is seen  in nearly half of cases. Immunohistochemically, 
chromophobe renal cell carcinoma is positive for EMA, ck7, CD9, CD82, 
paxillin, claudin-7 and -8, Ep-Cam (an epithelial adhesion molecule).(95) 
 
COLLECTING DUCT CARCINOMA 
 It accounts for approximately less than 1% of RCCs.(66) These 
tumors are more common in young males. They are centered in the 
medulla and have a tubulopapillary architecture, and are surrounded by a 
desmoplastic reaction.(96) The cells have a hobnail pattern with a 
eosinophilic cytoplasm.  The cells usually display  (Fuhrman 3 and 4) 
nuclear features. Both intraluminal and intracytoplasmic mucin may be 
seen. Atypical changes in the adjacent ducts are common. Cases with 
signet ring features are also reported.(97) 
 
 Vinculin is the immunohistochemical marker for this tumor type. 
The characteristic feature is a positive reaction to Ulexeuropaeus  and 
coexpression of low molecular weight CKs and high molecular weight 
CKs. Leu M1 and epithelial membrane antigen has a variable 
expression.(90) This clinically aggressive tumour, often shows metastases 
at presentation and characterised by rapid progression.(98) The typical 
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collecting duct carcinomas has  poor prognosis . Two thirds of patients 
die within two years of diagnosis. 
 
RENAL MEDULLARY CARCINOMA 
 This is a very rare tumour. This tumour characteristically occurs  in 
young black patients suffering from sickle cell disease.(99) They are  
centered in medulla and poorly circumscribed . Tumor` mean size is  
approximately 7 cm. Most of these tumours have multiple areas of 
haemorrhage and necrosis. Microscopically it exhibits a yolk sac-like , 
reticular  or adenoid cystic appearance and poorly differentiated areas. 
This tumour has  desmoplastic stroma with neutrophils and  marginated 
by lymphocytes.(100) Immunohistochemically, they are consistently 
positive for CEA. They are often reactive to CK20, CAM5.2, CK7 
AE1/AE3, and vimentin. (101) It has a very aggressive behaviour and 
usually present with metastasis. 
 
RENAL CARCINOMAS ASSOCIATED WITH XP11.2 
TRANSLOCATIONS / TFE3 GENE FUSION 
 These malignancies are characterised by different translocations in 
chromosome Xp11.2. All of these translocations in turn can cause gene 
fusions in the transcription factor binding to IGHM enhancer 3 (TFE3) 
gene. Children and young adults are predominantly affected by this 
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tumor.(102) These malignancies are usually characterised by an advanced 
stage of presentation .  
 
 On gross examination, they resemble Clear cell RCC and  most 
commonly tan or yellow and often with necrosis and haemorrhage. The 
most characteristic histopathologic feature is the papillary architecture 
comprised of cells having a clear to granular eosinophilic type of 
cytoplasm with distinct cell borders. These cells have vesicular nucleus 
with prominent nucleoli. In all these tumours, there is constant presence 
of psammoma bodies.(90) 
 
 TFE3 protein has a nuclear immunoreactivity and it is the most 
chararcteristic immunohistochemical feature of these tumours. 50% of 
tumors only express cytokeratin and EMA.(102) The tumours are also 
positive for  Renal Cell Carcinoma Marker antigen and CD10. 
 
RENAL CELL CARCINOMA ASSOCIATED WITH 
NEUROBLASTOMA 
 It occurs in adolescents with history of childhood neuroblastoma. 
Subsequent development of renal cell carcinoma in these patient is found 
to be caused by Neuroblastoma treatment. Median age at the time of 
diagnosis of Renal cell carcinoma was 13.5 years. Males and females 
have equal incidence rates. 
26 
 
 
 In these morphologically heterogeneous tumours, some  are 
characterized by solid and papillary architecture. The cells are  with 
abundant eosinophilic cytoplasm and some are with reticular cytoplasm, 
exhibiting  mild to moderate pleomorphism.(103) In other  group, the 
tumours are small, and clear cell RCC  were detected incidentally. These 
tumours are usually positive for vimentin, EMA, and keratins 8, 18, and 
20 .They  are negative for keratins 7, 14, and 19. 
 
MUCINOUS TUBULAR AND SPINDLE CELL  CARCINOMA 
 For the first time, this entity was included in the current WHO 
classification . Mean age is 53 year at the time of diagnosis .There is a 
female predominance. On ultrasound, it is usually found as an incidental 
mass. They are well circumscribed, grey or light tan with uniform cut 
surfaces. They are low-grade malignancies. 
 
 These  tumors were   composed of tubules which are tightly packed 
with pale mucinous stroma separating these tubules. The tubular arrays 
often have a spindle cell configuration. Distal nephron is likely to be the 
site of origin. But some believe it to be of proximal tubule origin as a 
papillary RCC variant. Rare cases exhibit sarcomatoid changes.(90) 
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RENAL CELL CARCINOMA, UNCLASSIFIED  
 This group accounts to 4-5% of RCC cases. Renal carcinoma that 
could not be fit into one of the other categories should be  classified into 
this diagnostic category.(104) Since this variety is comprised of tumours 
with varying appearances and genetic heterogenecity, it cannot be 
described to have specific histological features.  The features for defining  
unclassified RCC include 
 
a) Admixture of recognised types, 
b) Mucin production,   
c) Absence of recognisable epithelial elements with presence of 
distinct  sarcomatoid morphology, 
d) presence of both epithelial and stromal elements rarely,  
e) cell types with unrecognisable features. 
 
 At presentation, in comparison with  clear cell RCC,  unclassified 
type was found to have larger size of tumours, increased incidence of 
adrenal gland invasion, adjacent organs  invasion, regional  and 
nonregional lymph nodal involvement and metastasis to bone. On 
multivariate analysis, Unclassified histology itself  was an independent 
marker for poor outcome. Median survival of  patients suffering from 
unclassified  RCC was around 4.3 month.(90) 
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NUCLEAR GRADING : 
Skinner et al first proposed the nuclear grading system. Nuclear 
morphology was the basis for this grading system. In RCC, for 
demonstrating this system`prognostic value, Skinner et al carried out a 
study comprised of 272 patients. This study demostrated a high 
correlation of nuclear grade with patient survival rate in RCC.(105) 
 
Skinner grading system(106) 
 G1 – Nuclei are small, indistinguishable from those seen in normal 
tubular cells 
 G2 – Nuclei are slightly irregular and frequently pyknotic without 
abnormal nucleoli 
 G3 – Nuclei are irregular, enlarged and pleomorphic with 
prominent nucleoli 
 G4 – Nuclei are extremely giant and bizarre 
 
 In 1982, the nuclear grading system proposed by Skinner et al was 
simplified by Furhman et al. This four-tier system used the features such 
as size of nucleus and nucleoli, shape of nucleus and contents of nuclei. 
In this system for nuclear grading, regardless of their percentage, highest 
grade of any of its components is used to classify the entire neoplasm. 
Worldwide, this grading system is currently used for nuclear grading of  
RCC.(105) 
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Fuhrman grading system(107) 
 G1 – Nuclei are small, round and uniform (10 μm), with 
inconspicuous or absent nucleoli. 
 G2 – Nuclei are slightly irregular (15 μm), with small nucleoli. 
 G3 – Nuclei are very irregular (20 μm), with large and prominent 
nucleoli. 
 G4 – Nuclei exhibit large and pleomorphic often poly-lobed and 
bizarre (> 20 μm). 
 
 This grading system is used to assess the RCC prognosis, 
especially for conventional and papillary RCC. It is widely acceptable for 
its simplicity. Its correlation with different pathologic variables has been 
proven. Most of the controlled studies has confirmed its prognostic value 
in RCC patients. Poor prognostic outcome has been associated with grade 
3 or 4 of this system. Good prognostic outcome has been associated with 
grade 1 or 2 of this system. Intraobserver variability and interobserver 
variability has been the problem with this grading system and hence the 
reproducibility problem among pathologists.(65) 
 
TREATMENT OF LOCALIZED RCC 
 For localized RCC, radical nephrectomy  has been  the gold 
standard treatment option historically.(108) Nowadays, partial nephrectomy 
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(nephron-sparing surgery - NSS) is the standard treatment option 
recommended for localised renal neoplasms measuring up to  7 cm in 
diameter, and for larger neoplasms also, it can be the treatment option, 
whenever surgically feasible.(109,110) In prospective randomized studies the 
oncological efficacy of NSS is confirmed, and it has been proved that 
with NSS, incidence of renal insufficiency and  ill effects on day to day 
health has been reduced, and cardiovascular ill effects also reduced on 
comparison with radical nephrectomy.(111) 
 
 For some of the selected patients with RCC,  laparoscopic resection 
of renal masses has become the one of the standard treatment option. 
When compared to open surgery, laparoscopic renal surgery is associated 
with lower rate of morbidity,(110) for localised  renal tumours that are not 
suitable for NSS , laparoscopic nephrectomy  is the standard procedure 
and it also provides an equivalent prognostic outcomes in comparison 
with open surgery .(112) With experienced hands and with careful selection 
of patients, laparoscopic partial nephrectomy has been an effective 
alternative method to partial nephrectomy by open laparotomy.  
 
 Partial nephrectomy by means of Robotic-assistance is under trial. 
Role of lymphadenectomy in the management of  RCC patients  is  
currently restricted only for the purpose of staging, principally at the  
renal hilar region. In patients with retroperitoneal lymph nodal spread, 
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extended lymphadenectomy may improve  the survival rates of RCC 
patients. In case of patients with preoperative imaging showing normal 
adrenal gland, routine adrenalectomy is to be done only for large upper 
pole renal tumors or for renal tumours measuring more than 7 cm  
diameter.(110) 
 
Minimally-invasive procedures such as 
 cryoablation 
 percutaneous ablation by means of radiofrequency  
 microwave ablation  
 high-intensity focused ultrasound (HIFU), and 
 laser ablation(113)  
are alternative procedure for surgical resection in some of the selective 
RCC patients such as multiple tumours or poor overall health status. 
Active follow up can be advised for small renal tumours and treatment 
can be considered only if it shows significant  progression.(110) 
 
TREATMENT OF METASTASIZED RENAL CELL 
CARCINOMA 
 The typical feature of RCC is resistance against cytotoxic drugs, 
radiotherapy,  and hormones.(114) Immunotherapy with interleukin-2 (IL-
2) or interferon alpha (IFN-α)  can produce durable and complete 
responses. The response rate for IFN-α is found to be 6–15% and  for IL-
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2, response rate is 7-27%;  this provides only a modest benefit in terms of 
survival in patients with advanced stage of RCC. Currently, adjuvant use 
with bevacizumab is the only role of immunotherapy in patients with 
advanced stage of RCC.(110,114) 
 
 The Molecular targeted therapies are designed in order to block the 
critical signalling pathways which underlies the pathogenesis of RCC. 
Molecular targeted therapies are divided into three categories: 
multikinase and tyrosine kinase inhibitors, VEGF antibodies and mTOR 
inhibitors.(115) For metastasized RCC, these targeted therapies are  applied 
by a systemic route.(110) Clinical trials have proven the efficacy of 
molecular targeted therapies  where they have proved to improve both 
progression-free and overall survival.  Since these drugs do not eradicate 
the disease. Durable remissions can occur.(114,115) Better efficacy, 
tolerability, and oral administration are the advantages of molecular 
targeted therapies over immunotherapy.(115) 
 
 Patient survival can be improved by means of cytoreductive 
nephrectomy along with surgical resection of RCC metastases. They have 
been advised for RCC patients with a good overall health status.(110) Role  
of palliative surgery  for symptomatic brain and bone metastases must be 
re-evaluated by means of elaborative clinical trials, in view of  the recent 
achievements in molecular targeted therapies;(116) Palliative radiotherapy 
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is indicated if systemic treatment proves to be of no use. Severe pain due 
to metastases can be relieved by means of embolization of paravertebral 
and bone metastases.(110) 
 
PROGNOSTIC AND SURVIVAL FACTORS IN RCC 
 RCC has a variable clinical course. Incidentally discovered and 
small tumours have an indolent course even without treatment. Survival 
rates are poor  in metastasized  RCC or recurrent disease . The overall 
RCC prognosis has been greatly improved by means of diagnosis in early 
stages of the tumor and by means of significant advancement in 
anatomical imaging, surgical staging and different modes of 
treatment(both medical and surgical means).(117,5) Stage and grade are 
currently the most important RCC prognostic factors.(9) 
 
Clinical prognostic factors 
 Patients who are presenting with clinical symptoms are found to 
have decreased survival, whereas patients with incidentally found  tumors 
are  likely to have a more favourable prognosis, which can be explained 
by the incidence of smaller size of the renal mass and lower tumour stage 
at the time of diagnosis.(118,119,120) More than 10% body weight loss in 6 
months is found to have significantly lowered survival  rate. For 
predicting  poor prognosis, cachexia have been an independent 
indicator.(64,120) The overall health status, as assessed by the Karnofsky 
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scales or Eastern Cooperative Oncology Group (ECOG), can estimate the 
impact of RCC on the overall wellbeing of the patient, and have been 
accepted as the significant and established prognostic factors for RCC.(64) 
 
 Younger age of diagnosis has been established as an independent 
indicator of a more favourable outcome.(121) Gender does not have any 
prognostic potential.(119) 
 
 Patient survival rate can be correlated with many laboratory 
indices. Excessive interleukin-6 (IL-6) production by the advanced RCC 
leads to a relatively high CRP level compared to early stage RCC. This 
IL-6 is a cytokine with multifunctional growth factor activities and in turn 
can be a predictor for a more poor prognosis. Poor outcome of the RCC 
patient can also be predicted by the elevated erythocyte sedimentation 
rate and thrombocytosis.(64) In addition, haemoglobin, serum calcium, 
lactate dehydrogenase,   albumin,  neurone-specific enolase (NSE, γ-
enolase) and  alkaline phosphatase are also found to be of  prognostic 
value to some extent in RCC.(122) 
 
Prognostic anatomical factors: stage at diagnosis 
 The tumor staging is currently the most reliable indicator in RCC 
prognosis. For localized stage of disease, 5-year  survival rates following 
radical nephrectomy is  generally 75–95%; for locally advanced  stage of 
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RCC, it is 65–80%; for tumours extending into inferior  vena cava, it is 
40–60%; for RCC with lymph nodal extension, it is 10–20%; and for 
RCC with metastasis, it is 0–5%.(64) Staging takes into  account features 
like size  of the tumour, venous  extension , invasion into the renal 
capsule, involvement of adrenal gland, lymph nodal involvement and 
metastasis to distant organs, and  all of which are established  
independent prognostic markers and when they are assessed in 
combination by means of staging, provide the most dependable 
prognostic information in RCC patients.(9,123) The TNM classification for 
staging of RCC was revised recently in 2009.(124) In comparison to the 
previous 2002 version of staging(125), T2 tumour class is now sub 
classified into  T2a(tumours more than 7 cm but less than 10 cm in 
diameter) and T2b( tumours more than 10 cm in diameter), but both not 
extending beyond the limits of the kidney. In addition, RCC with a 
tumour thrombus extending only into the corresponding renal vein is now 
staged as T3a and invasion into adjacent adrenal gland is now staged as 
T4.(110) 
 
Histological prognostic factors 
 Despite strong criticism regarding the predictive value and validity 
of the Fuhrman grading system, untill now it is considered  the most 
reliable histological grading system available for RCC . It is accepted one 
36 
 
of the independent prognostic marker for clear cell variety of  RCCs.(121) 
The RCC-specific 5-year survival rate  is 89% in case of grade 1 tumours, 
65% in case of grade 2 tumours and 46% in case of grades III-IV 
tumours.(16) In general, the overall prognosis for papillary type of RCC 
and chromophobe type of RCC is much better than overall prognosis of 
clear cell type of RCC. The overall survival rate of collecting duct type of 
RCC is poor.(9,110) Among papillary type of RCCs, type 1 tumours 
generally have a better prognosis than  the prognosis of type 2, which 
itself is one of the independent indicators of a poor prognosis.(84) Among 
the different histological features of RCC, microscopic invasion of 
veins(MVI), sarcomatoid differentiation, collection system invasion and 
areas  of tumoural necrosis are correlated  with decreased survival rates.  
Cystic component of RCC is accepted as an independent marker to 
indicate more benign clinical outcome.(110,121) 
 
Molecular  prognostic factors  
 Numerous molecular markers  are being investigated which 
includes carbonic anhydrase IX (CaIX), vascular endothelial growth 
factor (VEGF), hypoxia-inducible factor (HIF), Ki67 (proliferation), p53, 
E-cadherin, C-reactive protein (CRP), CD44 (cell adhesion) and 
osteopontin. Gene expression profiling seems a promising method, to 
identify new relevant prognostic factors .(126) 
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Prognostic Factors In Metastasized Renal Cell Carcinoma 
 In advanced RCC, classic anatomical and histological features of 
the primary tumour  had limited predictive value.(9) The prognostic 
factors  identified in metastasized disease are performance status, time of 
appearance of metastases, number and locations of metastatic sites, prior 
nephrectomy and  surgical resection of metastases.(120) Metastases to bone 
have been regarded as a marker of shorter survival. Number of metastatic 
sites is considered as a more important prognostic marker than  location 
of metastasis.(64) 
 
IMMUNOHISTOCHEMISTRY:  
 Albert Coons et al in 1941 first labelled antibodies directly with 
fluorescent isocyanate. Nakane and Pierce et al in 1966, introduced the 
indirect labeling technique in which the unlabelled antibody is followed 
by second antibody or substrate. Various stages of development of 
Immunohistochemistry include peroxidase – antiperoxidase method 
(1970),  alkaline  phosphatase  labeling  (1971), avidin  biotin   method 
(1977) and two layer dextrin polymer technique (1993).(127) 
 
ANTIGEN RETRIEVAL:  
 Antigen retrieval can be done by the following different techniques 
to unmask the antigenic determinants of fixed tissue sections. 
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1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval 
3. Pressure cooker antigen retrieval 
4. Microwave and trypsin antigen retrieval 
 
PROTEOLYTIC ENZYME DIGESTION: 
 Huank et al in 1976 introduced this technique to breakdown 
formalin cross linkages and to unmask the antigen determinants. The 
most commonly used enzymes include trypsin and proteinase.(128) The 
disadvantages include over digestion, under digestion and antigen 
destruction. 
 
MICROWAVE ANTIGEN RETRIEVAL: 
 This is a new technique most commonly used in current practice. 
Microwave oven heating involves boiling formalin fixed paraffin sections 
in various buffers for rapid and uniform heating.(127) 
 
PRESSURE COOKER ANTIGEN RETRIEVAL: 
 Miller et al in 1995 compared and proved that pressure cooking 
method   has fewer inconsistencies, less time consuming and can be used 
to retrieve large number of slides than in microwave method.(129) 
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PITFALLS OF HEAT PRETREATMENT: 
 Drying of sections at any stage after heat pretreatment destroys 
antigenicity. Nuclear details are damaged in poorly fixed tissues. Fibers 
and fatty tissues tend to detach from slides while heating. Not all antigens 
are retrieved by heat pretreatment and also some antigens like PGP 9.5 
show altered staining pattern. 
 
DETECTION SYSTEMS: 
 After addition of specific antibodies to the antigens, next step is to 
visualize the antigen antibody reaction complex. The methods employed 
are direct and indirect methods.  
 
 In the direct method, primary antibody is directly conjugated with 
the label. Most commonly used labels are flouro-chrome, horse radish 
peroxidase and alkaline phosphatase. Indirect method is a two-step 
method in which labelled secondary antibody reacts with primary 
antibody bound to specific antigen. The use of peroxidase enzyme 
complex  oravidin biotin  complex  further  increases  the  sensitivity of 
immunohistochemical stains.(127) 
 
 In 1993, Pluzek et al introduced enhanced polymer one step 
staining, in which large numbers of primary antibody and peroxidase 
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enzymes are attached to dextran polymer back bone. This is the rapid and 
sensitive method.(130) 
 
 Dextran polymer conjugate two step visualization system is based 
on dextran technology in Epos system. This method has greater 
sensitivity and is less time consuming. 
 
Ki-67  
 Ki-67 also recognized as MKI67 is a protein encoded by the 
MKI67 gene (131) which was discovered by Gerdes. Originally this protein 
was defined by the prototype monoclonal antibody Ki-67 and it was 
generated by immunizing mice with nuclei of the Hodgkin lymphoma cell 
line L428. It was named based on the city of origin (Kiel, Germany) and 
the number of the original clone in the 96-well plate. 
 
 Ki-67 is a nuclear protein that is necessary for cellular proliferation 
and ribosomal RNA transcription. It is present during all active phases of 
the cell cycle (G1, S, G2, and M), but is absent from resting cells (G0). 
The protein is predominantly localized in the peri-nucleolar region in the 
G 1 phase, in the later phases it is also detected throughout the nuclear 
interior, being predominantly localized in the nuclear matrix having a half 
life of is 60-90 minutes. In mitosis, it is present on all chromosomes.(131) 
Thus Ki-67 is an excellent proliferation marker to determine the growth 
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fraction of a specified cell population and is widely as a proliferation 
marker in many of the human tumours. The fraction of Ki-67-positive 
tumor cells is often associated with the clinical course of various 
neoplasms. The monoclonal antibody generally used to detect the Ki-67 
antigen is MIB-1. One of its major merits over the original Ki-67 
antibody is that it can be applied on formalin-fixed paraffin-embedded 
sections, after heat-mediated antigen retrieval. Ki-67 labeling index is 
calculated by the percentage of tumours cells showing distinct brown 
staining of the nucleus with strong intratumoural heterogeneity. 
 
 Studies on RCC,  gastric cancer , bladder cancer , lymphomas, 
colorectal cancer  and breast cancer  have shown that overexpression of  
Ki67  is correlated with  biological behaviour and prognosis of these 
malignancies.(132) 
 
 The other methods of detection of Ki-67 are by Western blot 
analysis and immunofluorescence. The various other markers of 
proliferation include AgNOR staining, PCNA and Topoisomerase II. The 
novel markers being evaluated for identifying cell proliferation include 
Fen-1, MCM proteins (mini-chromosome maintenance), mitosin, polo – 
like kinase and claspin.  
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P53 
 p53 was first  identified in 1979 by David P. Lane, Lionel, Lloyd 
Old, and  Crawford Arnold Levine. in 1985, human TP53 gene was 
cloned. The role of P53 as a tumor suppressor gene was discovered by 
Bert Vogelstein in 1989. It is considered as the “Guardian of the 
genome”. This tumour suppressor gene is located on chromosome 
17p13.1. It encodes a nuclear phosphoprotein of 53kDa.(133) p53 plays a 
central  role  in cell – cycle regulation, in cell apoptosis and in DNA 
repair. When there is cellular insult or DNA damage there is  increased 
p53 production; then it induces  cell cycle arrest  at the G1/S junction. 
Therefore, for control of tumor growth, apoptosis and maintaining 
genome stability, p53 is essential.  Normal p53 protein, is rapidly 
removed from the nucleus but  mutant forms have  prolonged half-
life.This favours intranuclear accumulation and so it can be detectable 
immuno-histochemically. P53 appears mutated  in a wide variety of 
human carcinomas, such oral and oropharyngealcarcinoma, colorectal 
carcinoma, breast carcinoma,  esophageal carcinoma, gall bladder 
carcinoma and gastric carcinoma. In numerous studies there was  
correlation between  over expression of p53  gene and the poor prognosis 
in patients with these tumors. The p53 is also involved in regulating the 
metastasis-associated genes. These genes are  integrin, Maspin, matrix 
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metallo-proteinase-2 (MMP-2), MMP-13 and the tissue inhibitor of 
metalloproteinase-3 (TIMP3).  
 
 P53 appears  mutated in about 50% of many malignancies, but in 
RCC, incidence of p53 mutations  is  low. P53 mutations has been 
detectedin 3-33% of patients with RCC. Although in the majority of 
RCCs p53 remains wild type, this does not mean, that it is  functional. 
P53 function can also be repressed by  mechanisms, which  involve loss 
of positive regulators, such as Arf  or  overexpression of natural negative 
regulators,MDM2 or MDMX or by viral proteins, such as E6 of the 
human papilloma virus. 
 
 On comparing the association of p53 expression and nuclear grade, 
there are number of controversial studies. Some investigators have found 
no association but some of them demonstrated a strong relationship. 
However, p53 is considered as a potential marker in determining  
prognosis of patients with RCC.(133) It is now  known that like melanoma, 
RCC also  belongs to the type of tumors with a low incidence of p53 
mutations when compared to prostate and bladder.(134) 
 
 The most commonly used methods for detection of p53 mutations 
includes immunohistochemistry, polymerase chain reaction-single-strand 
conformation polymorphism(PCR – SSCP), flow-cytometry and genomic 
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sequencing. Although sequencing is the most unambiguous method, it is 
technically cumbersome. Therefore, both immune-detection and PCR 
have been used as alternative methods.  
 
MUC1 
 Mucins are high-molecular-weight  glycoproteins with 4200 kDa 
with oligosaccharides are attached to an apomucin protein   by O-
glycosidic linkage.(135) 
 
 The MUC1 gene is located on chromosome 1q21-24 .It is a 
member of mucin family which encodes a transmembrane glycoprotein. 
MUC1 is membrane-associated and membrane-secreted. MUC1 also is 
known as polymorphic urinary mucin, or PUM, and epithelial membrane 
antigen (EMA). MUC1 has a apical membranous distribution of many 
glandular epithelia like epithelium of the colon, breast, lung, pancreas and 
kidney. MUC1 is supposed to play a role in cellular polarity, cell 
adhesion and signal transduction. In the kidney, MUC1 is expressed in 
normal distal convoluted tubules, collecting ducts .(8) 
 
 Sialylated MUC1 mucin expressed on tumor cells suppresses 
cellmatrix adhesion and homotypic cellular aggregation and promotes 
invasion. In vitro, sialylated MUC1 mucin  also inhibits cytotoxic 
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lymphocyte–target cell interactions. They also induce apoptosis of  
lymphocytes. 
 
 Thus, with these findings cancer cells with a high level of  
sialylated MUC1 expression are able to detach easily from the primary 
lesion and they survive in circulation and in distant organs of metastasis 
by escaping  immune surveillance.(136) 
 
 In many epithelial cancers, there is loss of polarized cellular 
expression and there is diffuse circumferential distribution. These 
variations of expression of  MUC1 in malignant cells are suspected to be 
responsible for metastatic dissemination by destabilization of cell-cell and 
cell–extracellular matrix interactions. In various studies, MUC1  is 
considered as a marker of tumor progression and prognosis.(8) 
  
MATERIALS  
AND 
 METHODS 
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MATERIALS AND METHODS 
 
 This study is a combined retrospective and prospective study of 
renal cell carcinoma, conducted in the Institute of Pathology, and Rajiv 
Gandhi Government General Hospital, Chennai for a period of 3 years 
between august 2011  to august 2014 . 
 
 Total of 52 cases of resected specimens of renal cell carcinoma 
were received for histopathological examination in Madras Medical 
College during the period between august 2011 to august 2014. 
 
INCLUSION CRITERIA: 
 All resected specimens of renal cell carcinoma, irrespective of the 
age and stage were included for the study. 
 
EXCLUSION CRITERIA: 
1. Renal biopsy specimen 
2. Renal malignancies other than renal cell carcinoma 
3. Nephrectomy done for Benign and non-neoplastic lesion of kidney 
 
METHOD OF DATA COLLECTION: 
 Detailed history of the cases regarding age, sex, clinical 
presentation, investigations done along with the findings, type of 
procedure done were obtained for all the renal cell carcinoma specimens  
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received during the period of study. Haematoxylin and Eosin stained 4 
micron thick sections of the paraffin tissue blocks of the cases were 
prepared from nephrectomy specimens and cases reported as renal cell 
carcinoma were selected. 40 patients were randomly selected for 
Immunohistochemical analysis using ki67, p53 and MUC1 
 
Variables studied: 
The following clinical and pathological parameters were evaluated: 
 Age, gender, size, laterality (right or left side), histological types 
(clear cell RCC, papillary RCC, chromophobe RCC, unclassified RCC) 
 
Nuclear grading according to FURHMAN grading system.(107) 
 G1 – Nuclei are small, round and uniform (10 μm), with 
inconspicuous or absent nucleoli. 
 G2 – Nuclei are slightly irregular (15 μm), with small nucleoli. 
 G3 – Nuclei are very irregular (20 μm), with large and prominent 
nucleoli. 
 G4 – Nuclei exhibit large and pleomorphic often poly-lobed and 
bizarre (> 20 μm). 
 
 Presence of capsular infiltration, renal vessel invasion, ureter  
invasion and lymph node involvement, distant metastasis and TNM 
STAGING (ANNEXURE 3)were performed. Representative formalin 
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fixed, paraffin embedded tissue samples were subjected to 
immunohistochemical analysis with a panel of 3 markers i.e., ki67, p53 
and MUC1  
 
Antigen Vendor Species (clone) Dilution control 
KI67 PATHINSITU MOUSE Ready to use 
Malignant 
phyllodes 
P53 DAKO MOUSE Ready to use 
Colonic 
malignancy 
MUC1 PATHINSITU RABBIT Ready to use 
Distal 
Convoluted 
Tubule 
 
Immunohistochemistry procedure: 
Slide Preparation: 
1. Sections with a thickness of 4 μ were cut from formalin fixed 
paraffin embedded tissue samples and transferred to gelatin-
chrome alum coated slides. 
2. The slides were incubated for overnight at 58ºC. 
3. The sections were  deparaffinised in xylene for 15 minutes x 2 
changes. 
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4. The sections were dehydrated with absolute alcohol for 5 minutes 
for 2 changes. 
5. The sections were then washed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 5 minutes. 
 
Antigen Retrieval: 
1. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with appropriate buffer for 20 minutes. 
This step unmasks the antigenic determinants of fixed tissue 
sections. 
2. The slides were then cooled to room temperature for 20 minutes 
and washed in running tap water for 5 minutes. 
3. The slides were then rinsed in distilled water for 5 minutes. 
4. They were washed with appropriate wash buffer (phosphate buffer) 
for 5 minutes x 2 changes. 
5. Peroxidase block was applied over the sections for 10 minutes. 
6. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
7. Sections were covered with protein block for 5 minutes. 
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Antibody application: 
1. The sections were drained (without washing) and appropriate 
primary antibody was applied over the sections and incubated for 
30 minutes. 
2. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
3. The slides were covered with Primary antibody amplifier for 10 
minutes. 
4. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
5. The slides were covered with HRP micropolymerQuanto for 10 
minutes. 
6. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
 
Chromogen application: 
1. DAB substrate was prepared by diluting 1 drop of DAB 
Quantochromogen to 1 ml of DAB Quanto buffer. 
2. DAB substrate solution was applied on the sections for 5 minutes. 
3. The slides were washed in distilled water for 2 minutes. 
4. The sections were counterstained with Hematoxylin  for 2 seconds. 
5. The slides were washed in running tap water for 5 minutes. 
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6. The slides were air dried, cleared with xylene and mounted with 
DPX. 
 
INTERPRETATION AND SCORING SYSTEM 
Ki67 
 The immunohistochemically stained slides were analyzed for the 
presence of reaction and percentage of cells stained. Immunoreactivity 
was identified by nuclear brown color. The percentage of nuclei with 
immunoreactive ki67 was counted for each tumor slide. 
Immunoreactivity was classified as continuous data from undetectable 
levels (0%) to homogeneous (100%). The reaction is considered positive 
when 10% or more of the tumor cells showed staining, according to  
previous study.(134) 
 
P53 
 Immunoreactivity was identified by nuclear brown color. The 
percentage of nuclei with immunoreactive p53 was counted for each 
tumor slide. Immunoreactivity was classified as continuous data from 
undetectable levels (0%) to homogeneous (100%). 
 
Expression of p53 was evaluated separately using the following scale:(133) 
 3+ = high level (91-100% of positive cells) 
 2+ = medium level (11-90% of positive cells) 
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 1+ = low level (up to 10% of positive cells) 
 0= negative cells (0% of positive cells). 
 
 For  purpose of statistical analysis a sample is said to be positive if 
5% of cells are positive for p53.(137) 
 
MUC1 
 A cell was estimated as positive when the cytoplasm, cell 
membrane, or both were stained. The percentage of positively stained 
cells (positive rate) was determined for each tumor. Immunoreactivity 
was categorized as follows: 
 
 0 - no reactivity  
 1 - less than 10% of cancer cells positive 
 2 -  10–25% positive 
 3 -  25–50% positive 
 4 - 50–75% positive 
 5 -  75–90% positive 
 6 - more than 90% of cancer cells positive. 
 
 For statistical analysis, in accordance with previous studies, sample 
with more than 10% of tumor cells  positive immunostaining were 
considered as positive .(135) 
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STATISTICAL ANALYSIS: 
 The statistical analysis was performed using statistical package for 
social science software version 15.5 which consisted computing the 
frequency counts and percentages for qualitative variables and mean for 
the quantitative variables.  The expression of KI67, P53, MUC1 was 
correlated with clinico-pathological factors like age, gender, tumor size, 
histological types, nuclear grade, stage using pearson’s chi-square test. 
The p value was considered significant if below 0.05. 
 
  
 
OBSERVATION  
AND  
RESULTS 
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OBSERVATION AND RESULTS 
 
 From august 2011 to august 2013, a total of  31,237 cases were 
received for histopathological examination in the institute of pathology, 
Madras Medical College. Among this, 52 were nephrectomy specimens 
done for RCC. Of this, 36 were clear cell RCC, 8 were papillary RCC, 2 
were Chromophobe RCC, 6 were unclassified RCC. Clear cell RCC was 
the most common type. 
 
TABLE 1: DISTRIBUTION OF TYPE OF RENAL CELL 
CARCINOMA 
 
 Among the 52 cases of renal cell carcinoma, maximum 36 (69.23 
%) cases were of clear cell RCC and 2nd maximum 7 (15.3 %)  cases 
were of papillary RCC. Minimum cases 2(3.8%) were of chromophobe 
RCC. Unclassified cases were 6(11.5%). (TABLE1&CHART 1) 
 
TYPE N (%) 
Clear cell  RCC 36 (69.23%) 
Papillary RCC-Type I 7(13.5%) 
Papillary RCC-Type II 1(1.9%) 
Chromophobe RCC 2 (3.8%) 
RCC, Unclassified 6 (11.5%) 
TOTAL 52(100%) 
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TABLE 2: AGE WISE DISTRIBUTION OF RENAL CELL 
CARCINOMA 
 
 Among the 52 cases of renal cell carcinoma, maximum 16 (30.77 
%)  cases were reported in 41-50 years age group and 2nd maximum 12 
(23.08%)  cases were reported in 51-60 years age group. Minimum age 
group reported was 21-30 years. (TABLE 2 & CHART 2)  
AGE GROUP RCC (%) 
21 - 30 years 1 (1.92 %) 
31 - 40 years 9 (17.31 %) 
41 - 50 years 16 (30.77 %) 
51 - 60 years 12 (23.08%) 
61 - 70 years 11 (21.15%) 
>70 years 3(5.77 %) 
Total 52 (100%) 
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TABLE 3: AGE WISE DISTRIBUTION IN TYPES OF RENAL 
CELL CARCINOMA 
 
Age Clear cell RCC 
Papillary 
RCC 
Chromophobe 
RCC 
Unclassified 
RCC 
21-30 
Years 1(2.7%) 0(0%) 0(0%) 0(0%) 
31-40 years 
 6(16.6%) 2(25%) 0(0%) 1(16.6%) 
41 - 50 
years 11(30.5%) 3(37.5%) 0(0%) 2(33.3%) 
51 - 60 
years 9(25%) 0(0%) 0(0%) 3(50%) 
61 - 70 
years 7(19.4%) 3(37.5%) 1(50%) 0(0%) 
>70 years 2(5.6%) 0(0%) 1(50%) 0(0%) 
Total 36(100%) 8(100%) 2(100%) 6(100%) 
 
 Among 36 cases of clear cell renal cell carcinoma, maximum 11 
(30.5%) cases were reported in 41-50 years age group and the lowest 
incidence of 1(2.7%)  case  reported in age group 21-30 years and 2nd 
lowest incidence of 2 cases were reported in age group >70 years.  
Totally 8 cases of papillary RCC were reported and of this, 75% cases 
were reported in the age group of 41-70%; lowest age group 31-40 years 
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were reported in 25% of papillary RCC cases. Only 2 cases of 
chromophobe RCC were reported which are more than 60 years. Of the 
unclassified type 3(50%) cases were reported in the age of 51-60 
years.(TABLE 3) 
 
TABLE 4: SEX WISE DISTRIBUTIONS OF RENAL CELL 
CARCINOMA 
SEX RCC (%) 
Male 38(73.08 %) 
Female 14 (26.92 %) 
Total 52 
 
 Among the 52 cases of renal cell carcinoma, 38(73.08 %) cases 
were reported in males and 14 (26.92 %) cases were reported in females. 
The male to female ratio was 2.7:1. (TABLE 4& CHART 3)  
 
TABLE 5: SIDE WISE DISTRIBUTION OF RENAL CELL 
CARCINOMA 
 
SIDE RCC (%) 
Right 35 (67.31 %) 
Left 17 (32.69 %) 
Total 52 
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 Among the 52 cases of renal cell carcinoma, 35 (67.31 %) cases 
were reported on right side and 17 (32.69 %)  cases were reported on left 
side. The right to left side ratio was 2.1:1. (TABLE 5 & CHART 4) 
 
TABLE 6: DISTRIBUTION OF  RENAL CELL CARCINOMA 
BASED ON THE SIZE 
Size No Of Cases Percentage % 
≤5 cm 14 26.9 
>5 cm 38 73.1 
Total 52 100 
 
 In this study 38(73.1%) tumors were of size more than 5 cm. 
14(26.9%) tumors were of size less than or equal to 5 cm. Median 
diameter of the tumor is 7.5 cm. (TABLE 6 & CHART 5) 
 
TABLE 7: DISTRIBUTION OF TYPES OF RENAL CELL 
CARCINOMA BASED ON THE SIZE 
 
Size Clear Cell RCC (%) 
Papillary 
RCC (%) 
Chromophobe 
RCC (%) 
Unclassified 
RCC (%) 
≤5 cm 11(30.6%) 3(37.5%) 0(0%) 0(0%) 
>5 cm 25(69.4%) 5(62.5%) 2(100%) 6(100%) 
Total 36 8 2 6 
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 In clear cell RCC, 69.4% were more than 5 cm. In papillary RCC 
62.5% were more than 5 cm. In chromophobe RCC and unclassified type, 
all the tumors were more than 5 cm. (TABLE 7& CHART 6) 
 
 
TABLE 8: GRADE AT PRESENTATIONAMONG  RENAL CELL 
CARCINOMA 
 
GRADE RCC (%) 
1 9(17.3 %) 
2 16(30.8 %) 
3 17(32.7%) 
4 10(19.2 %) 
Total 52(100%) 
 
 Among the 52 cases of renal cell carcinoma, maximum 17(32.7%) 
cases were of grade 3 and 2nd maximum 16(30.8 %) cases were of grade 
2. (TABLE 8 & CHART 7) 
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TABLE 9: GRADE AT PRESENTATION AMONG   
RENAL CELL CARCINOMA 
NUCLEAR   
GRADE 
CLEAR 
CELL 
RCC 
PAPILLARY 
RCC 
CHROMOPHOBE 
RCC 
UNCLASSIFIED 
RCC 
1 8 1 0 0 
2 12 3 1 0 
3 11 2 1 3 
4 5 2 0 3 
Total 36 8 2 6 
 
 In this study clear cell RCC cases were seen in all grades. Most of 
them were in grade 2 and 3. Most of the papillary RCC were of grade 2. 
One of the chromophobe RCC was grade 2 and the other was grade 
3.Unclassified RCC were of grade3 and grade 4.(TABLE 9 & CHART 8) 
 
TABLE 10: DISTRIBUTION OF CAPSULE INFILTRATION 
AMONG  RENAL CELL CARCINOMA 
 
Capsule infiltration RCC (%) 
Present 19(36.5%) 
Absent 33(%) 
Total 52 
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 Among the 52 cases of renal cell carcinoma, capsule infiltration 
was present among 17(36.5 %) cases and absent among 33(63.5 %) cases. 
(TABLE 10 )  
 
TABLE 11: DISTRIBUTION OF  PERINEPHRIC TISSUE 
INVOLVEMENT AMONG  RENAL CELL CARCINOMA 
 
PERINEPHRIC TISSUE 
INVOLVEMENT RCC (%) 
Present 13(25%) 
Absent 39(75%) 
Total 52 
 
 Among the 52 cases of renal cell carcinoma, perinephric tissue 
involvement was present among 13(25 %) cases and absent among 39 (75 
%) cases. (TABLE 11) 
 
TABLE 12: DISTRIBUTION OF GEROTA’S FASCIA 
INVOLVEMENT AMONG  RENAL CELL CARCINOMA 
 
GEROTA’SFASCIA 
INVOLVEMENT RCC (%) 
Present 5(9.6%) 
Absent 47(90.4%) 
Total 52 
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 Among the 52 cases of renal cell carcinoma, Gerota’s fascia 
involvement was present among 5(9.6 %) cases and absent among 47 
(90.4 %) cases. (TABLE 12) 
 
TABLE 13: DISTRIBUTION OF URETER INVASION AMONG  
RENAL CELL CARCINOMA 
URETER INVASION RCC  (%) 
Present 4(7.7%) 
Absent 48(92.3%) 
Total 52 
 
 Among the 52 cases of renal cell carcinoma, ureteric invasion was 
present among 4(7.7 %) cases and absent among 48(92.3%) cases. 
(TABLE 13) 
 
TABLE 14: DISTRIBUTION OF RENAL VESSEL INVASION 
AMONG  RENAL CELL CARCINOMA 
 
RENAL VESSEL 
INVASION RCC   (%) 
Present 10(19.2%) 
Absent 42(80.8%) 
Total 52 
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 Among the 52 cases of renal cell carcinoma, renal vessel invasion 
was present among 10(19.2%) cases and absent among 42(80.8 %) cases. 
(TABLE 14 ) 
 
TABLE 15 : DISTRIBUTION OF ADRENAL INVOLVEMENT 
AMONG  RENAL CELL CARCINOMA 
 
ADRENAL 
INVOLVEMENT RCC (%) 
Present 4(7.7%) 
Absent 48(92.3%) 
Total 52 
 
 Among the 52 cases of renal cell carcinoma, adrenal involvement 
was present among 4(7.7 %) cases and absent among 48(92.3 %) cases. 
(TABLE 15 ) 
 
TABLE 16: DISTRIBUTION OF REGIONAL LYMPHNODAL 
INVOLVEMENT AMONG  RENAL CELL CARCINOMA 
 
Regional lymphnodal 
involvement RCC (%) 
Present 4(7.69 %) 
Absent 48(92.31 %) 
Total 52 
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 Among the 52 cases of renal cell carcinoma, regional lymphnodal 
involvement was  present among 4(7.69 %) cases and absent among 
48(92.31 %) cases.  
 
TABLE 17: DISTRIBUTION OF DISTANT METASTASIS 
AMONG  RENAL CELL CARCINOMA 
 
DISTANT METASTASIS RCC (%) 
Present 3(5.8%) 
Absent 49(94.2 %) 
Total 52 
 
 Among the 52 cases of renal cell carcinoma, distant metastasis was  
present among 3(5.8 %) cases and absent among 49(94.2 %) cases. 
 
TABLE 18: T stage AT PRESENTATION AMONG   
RENAL CELL CARCINOMA 
T stage at presentation RCC (%) 
T1a 7(13.5%) 
T1b 11(21.6%) 
T2a 9 (17.3%) 
T2b 4(7.7% ) 
T3a 11(21.6%) 
T3b 3(3.8%) 
T3c 1(1.9%) 
T4 6 (11.5%) 
Total 52 
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 Among the 52 cases of renal cell carcinoma, maxium 11(21.6%) 
cases were presented at T1b stage and T3a. Minimum 6(11.5%) cases 
were presented at T4 stage. (TABLE 18 & CHART 9) 
 
TABLE 19: T STAGE AT PRESENTATION AMONG TYPES OF 
RENAL CELL CARCINOMA 
T STAGE 
CLEAR 
CELL 
RCC 
PAPILLARY 
RCC 
CHROMOPHOBE 
RCC 
UNCLASSIFIED 
RCC 
T1 12 6 0 0 
T2 11 1 1 0 
T3 9 1 1 4 
T4 4 0 0 2 
TOTAL 36 8 2 6 
 
 Most of the clear cell RCC and papillary RCC were presented in 
T1stage. Chromophobe RCC were presented in T2 stage and T3 stage. 
Most of the unclassified type presented in T3 stage. (TABLE 19) 
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TABLE 20: STAGE AT PRESENTATION  AMONG  RENAL 
CELL CARCINOMA 
 
STAGE RCC   (%) 
1 18(34.6%) 
2 13(25%) 
3 14(26.9%) 
4 7(13.5%) 
Total 52(100%) 
 
 Among the 52 cases of renal cell carcinoma, maximum 18(34.6 %) 
cases were presented at stage 1 and 2nd maximum 14(26.9 %) cases were 
presented at stage 3. Minimum cases 7(13.5%) were presented at stage 4. 
(TABLE 20) 
 
TABLE 21 : STAGE AT PRESENTATION AMONG TYPES OF 
RENAL CELL CARCINOMA 
 
 
STAGE 
CLEAR 
CELL 
RCC 
PAPILLARY 
RCC 
CHROMO 
PHOBE RCC 
UNCLASSIFIED 
RCC TOTAL
1 12 6 0 0 18 
2 11 1 1 0 13 
3 9 1 1 3 14 
4 4 0 0 3 7 
Total 36 8 2 6 52 
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 Most of the clear cell RCC were presented in stage 1. Most of the 
papillary RCC were presented in stage 1. Chromophobe  RCC were 
presented in stage 2 and stage 3. Unclassified RCC were presented in 
stage 3and 4.  (TABLE 21 & CHART 10) 
 
TABLE  22 :DISTRIBUTION OF CASES ACCORDING TO KI67 
EXPRESSION IN RENAL CELL CARCINOMA 
 
 In this study 72.5% of  tumors were positive for KI67 and 27.5% 
were negative for KI67. (TABLE 22 & CHART 11) 
 
TABLE 23 : DISTRIBUTION OF CASES ACCORDING TO KI67 
EXPRESSION IN TYPES OF RENAL CELL CARCINOMA 
Types of RCC KI67 Positive KI67 Negative Total 
Clear cell RCC 20(74%) 7(26%) 27(100%) 
Papillary RCC 5(71.4%) 2(28.6%) 7(100%) 
Chromophobe RCC 2(100%) 0(0%) 2(100%) 
Unclassified RCC 2(50%) 2(50%) 4(100%) 
Total 29 11 40 
Chi Square Test P Value-0.612 
 
KI67 RCC (N) Percentage 
Positive 29 72.5% 
Negative 11 27.5% 
Total 40 100% 
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 In this study, 74% of clear cell RCC were  positive  for  KI67. In 
papillary RCC, 71.4% were positive for KI67. All chromophobe RCC 
were positive for KI 67. 50% of unclassified tumors were positive for 
KI67.  There is no significant correlation between KI67 expression and 
tumor types. (TABLE 23 & CHART 12) 
 
TABLE  24 : DISTRIBUTION OF CASES ACCORDING TO KI67 
EXPRESSION IN CORRELATION WITH NUCLEAR GRADE 
NUCLEAR 
GRADE KI67 positive KI67 negative Total 
Grade 1 2(28.5%) 5(71.4%) 7(100%) 
Grade 2 7(63.6%) 4(36.4%) 11(100%) 
Grade 3 11(91.7%) 1(8.3%) 12(100%) 
Grade 4 9(90%) 1(10%) 10(100%) 
Total 29 11 40 
Chi-square test P value- 0.012 
 
 In this study in grade 1 tumors, 71.4% were negative for KI67. In 
grade 2 tumors, 63.6% were positive for KI67. In grade 3 tumors, 91.7% 
were positive for KI67. In grade 4 tumors,  90% were positive for KI67. 
There was positive correlation between KI67 and nuclear grade. (TABLE 
24 & CHART 13) 
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TABLE 25 : DISTRIBUTION OF CASES ACCORDING TO  
MEAN KI67 LABELLING INDEX IN CORRELATION  
WITH NUCLEAR GRADE 
Nuclear grade NO.OF CASES Mean KI 67 LI 
G1 7 5.6% 
G2 11 16.7% 
G3 12 36.9% 
G4 10 59.7% 
 
 In  this study in grade 1 tumors,  mean labelling index(LI) was 
5.6%. In grade 2 tumors, mean labelling index was 16.7%. In grade 3 
tumors, mean labelling index was 36.9%. In grade 4 tumors,  mean 
labelling index was 59.7%. There is increase in proliferative index with 
increase in nuclear grade. (TABLE 25 & CHART 14) 
 
TABLE 26: DISTRIBUTION OF CASES ACCORDING TO  LOW 
AND HIGH LEVEL OF KI 67 EXPRESSION IN CORRELATION 
WITH NUCLEAR GRADE 
NUCLEAR GRADE KI 67 1-10%(Low) 
KI 67  
>10%(high) 
Grade 1 4 2 
Grade 2 3 7 
Grade 3 1 10 
Grade 4 1 9 
Total 9 28 
Chi-Square Test P value 0.036 
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In grade 1 tumor, 4 (66.6%) showed expression <10%. 
In grade 2 tumor, 7(77.7%) showed expression >10%. 
In grade 3 tumor, 10(90%) showed expression >10%. 
In grade 4 tumor, 1(90%) showed expression >10%. (TABLE 26) 
 
TABLE 27: DISTRIBUTION OF CASES ACCORDING TO  
LOWAND HIGH LEVEL OF KI 67 EXPRESSION IN TYPES OF 
RENAL CELL CARCINOMA 
 
 In this study, 19(76%) of clear cell RCC had KI 67 expression 
>10%.In papillary RCC, 5(83%) had expression >10%. All chromophobe  
RCC had expression >10%.(TABLE 27) 
 
Types of RCC KI 67   1 -10% (Low) 
KI 67 
>10%(high) Total 
Clear cell RCC 6 19 25 
Papillary RCC 1 5 6 
Chromophobe RCC 0 2 2 
Unclassified RCC 2 2 4 
Chi Square Test P value 0.519 
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CORRELATION OF KI67 EXPRESSION WITH OTHER 
CLINICO -PATHOLOGICAL FACTORS 
 
TABLE 28: CORRELATION OF AGE WITH  
KI 67 EXPRESSION IN RCC 
AGE KI67 POSITIVE KI67 NEGATIVE TOTAL 
<=50 15 7 22 
>50 14 4 18 
Chi-square test P value-0.499 
 
 In this study, among  22 cases, 15 were positive for KI67 
expression in age less than  or equa to 50 years. In the age greater than 50 
years, 14 cases were positive for KI 67. There is no correlation between 
age and KI67 expression . (TABLE 28) 
 
TABLE 29: CORRELATION OF SEX WITH  
KI67 EXPRESSION IN RCC 
SEX KI67 POSITIVE KI67 NEGATIVE TOTAL 
Male 21 7 29 
Female 8 4 11 
Chi-square test P Value-0.589 
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 In this study, among 29males,  KI67 expression was seen in 21; 
Among 11 females, KI67 expression was seen in 8. There is no 
correlation between sex and KI67. (TABLE 29) 
 
TABLE 30: CORRELATION OF SIZE WITH  
KI67 EXPRESSION IN RCC 
SIZE KI67 POSITIVE KI67 NEGATIVE TOTAL 
<=5CM 6 4 10 
>5 CM 23 7 30 
Chi-square test P VALUE-0.307 
 
 In this study, 10 tumors were of size less than or equal to 5 cm . Of 
this, 6 were positive for KI67.  There is no correlation between size of the 
tumor  and KI67 expression. (TABLE 30) 
 
TABLE 31: CORRELATION OF STAGE  WITH KI67 
EXPRESSION IN RCC 
STAGE KI67 POSITIVE KI67 NEGATIVE TOTAL 
1 6 8 14 
2 8 1 9 
3 11 1 12 
4 4 1 5 
Chi-square test P VALUE- 0.021 40 
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 Among 17 stage 3 and stage 4 cases, 15 were positive for positive 
for KI67. Among 24 stage 1 and stage 2 cases, 14 were positive for KI67. 
Stage 3 and 4 shows more positivity when compared to stage 1 and 2. 
There is positive correlation between stage and KI67 expression in this 
study. (TABLE 31) 
 
TABLE 32  : DISTRIBUTION OF CASES ACCORDING TO P53 
GRADING IN   RENAL CELL CARCINOMA 
 
P53 GRADE TOTAL PERCENTAGE 
0 20 50% 
1+(1-10%) 10 25% 
2+(11-90%) 9 22.5% 
3+(91-100%) 1 2.5% 
TOTAL 40 100% 
 
 In this study, 20(50%) of RCC cases were not immunoreactive for 
P53. 25% of RCC expressed P53 in the range of 1-10%.  Medium 
expression of P53 was seen in 22.5% of cases. Maximum expression  of 
P53 was seen in 2.5% of cases. (TABLE 32) 
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TABLE   33: DISTRIBUTION OF CASES ACCORDING TO P53 
GRADING IN TYPES OF RENAL CELL CARCINOMA 
Types of 
RCC 
P53 GRADE 
0 1+ 2+ 3+ TOTAL 
Clear cell 
RCC 15(55.6%) 8(29.6%) 4(14.8%) 0(0%) 27(100%)
Papillary 
RCC 2(86.6%) 2(86.6%) 3(42.9%) 0(0%) 7(100%) 
Chromophobe 
RCC 0(0%) 0(0%) 2(100%) 0(0%) 2(100%) 
Unclassified 
RCC 3(75%) 0(0%) 0(0%) 1(25%) 4(100%) 
Total 20 10 9 1 40 
Chi Square 
Test P value -0.016 
 
 In this study, 29.6 % of clear cell  RCC showed  p53 expression in 
the range of 1-10%. 55.6% of clear cell RCC were not immunoreactive 
for p53. 42.9% of papillary RCC showed p53 expression in the range of 
11-90%. Only 2 chromophobe RCC studied which showed p53 
expression in the range of 11-90%. 75% of unclassified tumors were not 
immunoreactive for p53. P value is significant  between  p53 expression 
and types of RCC. (TABLE 33) 
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TABLE 34: DISTRIBUTION OF CASES ACCORDING TO P53 
GRADE IN   CORRELATION WITH NUCLEAR GRADE 
 
NUCLEAR 
GRADE 
P53 GRADE 
0 1+ 2+ 3+ TOTAL 
Grade 1 6 1 0 0 7 
Grade 2 5 3 3 0 11 
Grade 3 4 5 3 0 12 
Grade 4 5 1 3 1 10 
Total 20 10 9 1 40 
Chi-square 
test P VALUE-0.347 
 
 Among  7  grade 1 tumors, 6(85.7 %) were not immunoreactive for 
p53. In grade 2 tumors, 5(45.4 %) were not immunoreactive for 
p53expression.  6(54.5 %) of tumor showed p53  expression in the range 
of 1-90%. In grade 3 tumors 4(33.3 %) were not immunoreactive for 
p53expression. 5(41.7 %) of tumor  showed p53 expression  in the range 
of 1-10%. In grade 4 tumors, 5(50 %) were not immunoreactive for p53 
expression. 4(30 %)  of tumor  showed p53 expression  in the range of 
11-90%. P value is found to be insignificant between p53 expression and 
nuclear grade. (TABLE 34) 
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TABLE  35 : DISTRIBUTION OF CASES ACCORDING TO P53 
EXPRESSION IN   RENAL CELL CARCINOMA 
 
P53 TOTAL Percentage 
Positive 10 25% 
Negative 30 75% 
Total 40 100% 
 
 In this study, 30(75%) cases were negative for p53 expression. 
10(25 %)  cases were positive for p53 expression. (TABLE 35 &  
CHART 15). 
 
TABLE  36 : DISTRIBUTION OF CASES ACCORDING TO P53 
EXPRESSION IN TYPES OF    RENAL CELL CARCINOMA 
 
TYPES OF RCC P53  POSITIVE 
P53  
NEGATIVE TOTAL 
Clear cell RCC 4(14.8%) 23(85.2%) 27(100%) 
Papillary RCC 3(42.9%) 4(57.1%) 7(100%) 
Chromophobe RCC 2(100%) 0(0%) 2(100%) 
Unclassified RCC 1(25%) 3(75%) 4(100%) 
Total 10 30 40(100%) 
Chi Square Test P VALUE-0.03 
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 In this study, out of 27 clear cell RCC cases, 23(85%) cases  of 
clear cell RCC were negative for P53 expression. Of 7 papillary RCC 
studied, 4(57.1%) cases were negative for P53 and 42.9% were positive 
for P53. All 2 chromophobe RCC showed positivity for p53. 25% of 
unclassified type showed positivity for p53. (TABLE 36 & CHART 16) 
 
TABLE  37: DISTRIBUTION OF CASES ACCORDING TO P53 
EXPRESSION IN  CORRELATION WITH NUCLEAR GRADE 
NUCLEAR 
GRADE 
P53  
POSITIVE 
P53  
NEGATIVE 
Total 
 
Grade 1 0(0%) 7(100%) 7(100%) 
Grade 2 3(27.3%) 8(72.7%) 11(100%) 
Grade 3 3(25%) 9(75%) 12(100%) 
Grade 4 4(40%) 6(60%) 10(100%) 
Total 10 30 40 
Chi-square test P VALUE-0.313 
  
 In this study, all RCC cases with nuclear grade1 were negative for 
p53 expression. In cases with nuclear  grade 2 , 27.3% of cases were 
positive for p53. In cases with nuclear  grade 3 tumors,  25% of cases 
were positive for p53. In  cases with nuclear grade 4 tumors,  40% of 
them were positive for p53. Expression of p53 did not correlate with 
nuclear grade. (TABLE 37 & CHART 16) 
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CORRELATION OF P53  EXPRESSION WITH VARIOUS 
CLINICO PATHOLOGICAL   FACTORS 
 
TABLE  38 :CORRELATION OF AGE WITH  
P53  EXPRESSION IN RCC 
AGE P53 POSITIVE P 53 NEGATIVE TOTAL 
≤50 7 15 22 
>50 3 15 18 
Chi-Square Tests P Value-0.271 
 
 In this study, 7cases were positive for P53 in the age of less than or 
equal to 50 years. 3 cases were positive for P53 in the age group more 
than 50 years. There is no correlation between age and P53expression. 
(TABLE 38)  
 
TABLE  39 :CORRELATION OF SEX WITH  
P53  EXPRESSION IN RCC 
SEX P53 POSITIVE P 53 NEGATIVE TOTAL 
Male 6 22 28 
Female 4 8 12 
Chi-Square Tests P value-0.426 
 
 In this study, 6 males were positive for P53 expression and 4 
females were positive for P53. There is no correlation between sex and 
P53 expression. (TABLE 39) 
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TABLE  40 :CORRELATION OF SIZE WITH  
P53  EXPRESSION IN RCC 
SIZE P53 POSITIVE P53 NEGATIVE TOTAL 
≤5cm 1 8 9 
>5 cm 9 22 31 
Chi-Square Tests P VALUE-0.274 40 
 
 In this study, 22 tumors were of  size more than 5 cm; among this, 
9 were positive for P53 and one tumor with size less than or equal to 5cm 
positive for P53. There is no correlation between size of the tumor and 
P53 expression. (TABLE 40) 
 
TABLE  41 :CORRELATION OF STAGE WITH P53  
EXPRESSION IN RCC 
 
STAGE P53 POSITIVE P53 NEGATIVE TOTAL 
1 2 12 14 
2 2 7 9 
3 4 8 12 
4 2 3 5 
Chi-Square 
Tests P value-0.585 40 
          
 In this study, stage 3 cases had maximum P53 expression. There is 
no  significant correlation between stage and P53 expression.  
(TABLE 41) 
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TABLE  42 : DISTRIBUTION OF CASES ACCORDING TO MUC1 
GRADING IN   RENAL CELL CARCINOMA 
 
MUC1 GRADE TOTAL 
0 1(2.5%) 
1(<10%) 4(10 %) 
2(10-25%) 3(7.5 %) 
3(25-50%) 5(12.5 %) 
4(50-75%) 7(17.5 %) 
5(75-90%) 13(32.5 %) 
6>90% 7(17.5 %) 
TOTAL 40(100 %) 
 
 In this study, 32.5% of RCC expressed MUC1 in the range of 75-
90%. Maximum expression of MUC1 was seen in 17.5% of RCC. Grade  
2 expression was seen in 7.5% of cases. 2.5% of cases did not take up the 
stain. (TABLE 42) 
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TABLE  43 : DISTRIBUTION OF CASES ACCORDING TO MUC1 
GRADING IN TYPES OF  RENAL CELL CARCINOMA 
Types of 
RCC 
MUC1 GRADE 
0 1 
<1
0%
 
2 
(1
0-
25
%
) 
3 
 
(2
5-
50
%
) 
4 
(5
0-
75
%
) 
5 
(7
5-
90
%
) 
6 
>9
0%
 
Total 
Clear cell 
RCC 
1 
3.7% 
3 
11.1% 
2 
7.4% 
4 
14.8% 
3 
11.1% 
9 
22.5 
% 
5 
18.6% 
27 
100% 
Papillary 
RCC 
0 
0% 
1 
14.3% 
0 
0% 
1 
14.3% 
2 
28.5% 
2 
28.6% 
1 
14.3% 
7 
100% 
Chromo 
phobe RCC 
0 
0% 
0 
0% 
1 
50% 
0 
0% 
1 
50% 
0 
0% 
 
0 
0% 
2 
100% 
Unclassified 0 0% 
0 
0% 
0 
0% 
0 
0% 
1 
25% 
2 
50% 
1 
25% 
4 
100% 
Total 1 4 3 5 7 13 7 40 
Chi Square 
Test P value-0.856 
 
 In clear cell RCC, maximum cases(22.5%) expressed MUC1 in the 
range of 75-90%. Maximum  expression (>90%) is seen in 18.5% cases 
of clear cell RCC. Lowest expression (<10% ) is seen in 11.1% of clear 
cell RCC. 
 
 In papillary RCC, 57.2% of cases expressed  MUC1 in the range  
of 50-90%. In chromophobe RCC, expression of MUC1 ranged from 10-
75 %. In unclassified type, the expression of MUC1 is in the range of 25-
100 %. (TABLE 43 ) 
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TABLE  44 : DISTRIBUTION OF CASES ACCORDING TO MUC1 
GRADING IN   RENAL CELL CARCINOMA IN CORRELATION 
WITH NUCLEAR GRADE 
 
NUC 
LEAR 
GRADE 
MUC1 GRADE 
0 
 
1 
<1
0%
 
2 
(1
0-
25
%
) 
3 
(2
5-
50
%
) 
4 
(5
0-
75
%
) 
5 
 
(7
5-
90
%
) 
6 
>9
0%
 
Total 
1 1 14.3% 
2 
28.6% 
1 
14.3% 
0 
0% 
1 
14.3% 
1 
14.3% 
1 
14.3% 
7 
100% 
2 0 0% 
2 
28.6% 
1 
9.0% 
4 
36.4% 
2 
18.2% 
2 
18.2% 
0 
0% 
11 
100% 
3 0 0% 
0 
0% 
1 
8.3% 
1 
8.3% 
4 
33.3% 
5 
41.7% 
1 
8.3% 
12 
100% 
4 0 0% 
0 
0% 
0 
0% 
0 
0% 
0 
0% 
5 
50% 
5 
50% 
10 
100% 
TOTAL 0 4 3 5 7 13 7 40 
Chi 
Square 
Test 
P VALUE-0.015 
 
 In this study, 28.6% of grade 1 RCC cases showed  <10% MUC1 
expression.  
 36.4% of grade 2 RCC cases showed MUC1 expression in the range 
of 25-50%. 
 In grade 3 RCC, 41.7% cases showed MUC1 expression in  the range 
of 75-90% 
 In  grade 4 RCC, 100% cases showed MUC1 expression in  the range 
of  75-100%. 
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 In this study, when nuclear grade is increased, expression of MUC1 is 
also increased. (TABLE 44) 
 
TABLE  45 : DISTRIBUTION OF CASES ACCORDING TO MUC1 
EXPRESSION  IN   RENAL CELL CARCINOMA 
MUC1 TOTAL PERCENTAGE 
POSITIVE 35 87.5% 
NEGATIVE 5 12.5% 
TOTAL 40 100% 
 
 In this study, 87.5% cases  of RCC cases were positive for MUC1. 
12.5% cases were negative for MUC1 expression. (TABLE 45 & 
CHART 18) 
 
TABLE 46 : DISTRIBUTION OF CASES ACCORDING TO MUC1 
EXPRESSION IN TYPES OF   RENAL CELL CARCINOMA 
TYPES OF RCC MUC1 POSITIVE 
MUC1 
NEGATIVE TOTAL 
Clear cell RCC 23 4 27 
Papillary RCC 6 1 7 
Chromophobe RCC 2 0 2 
Unclassified RCC 4 0 4 
Total 35 5 40 
Chi Square Test P VALUE-0.799 
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 In this study, 23(85%) cases of clear cell RCC were positive for 
MUC1 expression. In papillary RCC, out of 7 cases, 6 were positive for 
MUC1 expression. 
 
 All 2 chromophobe cases showed positive MUC1 expression.  
All  4 unclassified  cases showed positive  MUC1 expression. (TABLE 
46 & CHART 19) 
 
TABLE  47 : DISTRIBUTION OF CASES ACCORDING TO MUC1 
EXPRESSION  IN   RENAL CELL CARCINOMAIN 
CORRRELATION WITH NUCLEAR GRADE 
NUCLEAR 
GRADE 
MUC1 
POSITIVE 
MUC1 
NEGATIVE TOTAL 
Grade 1 4(57.2%) 3(42.8%) 7(100%) 
Grade 2 9(81.8%) 2(18.1%) 11(100%) 
Grade 3 12(100%) 0(0%) 12(100%) 
Grade 4 10(100%) 0(0%) 10(100%) 
Total 35 5 40 
Chi-square test P value-0.025 
 
 In this study  in  RCC with nuclear grade 1,  57.2% cases were 
positive for MUC1 expression.  
 In  RCC with nuclear grade 2,  81.8 % cases were positive for 
MUC1 expression. 
85 
 
 In  RCC with nuclear grade 3,  100% cases were positive for 
MUC1 expression. 
 In  RCC with nuclear grade 4,  100% cases were positive for 
MUC1 expression.  
 There is a positive correlation between expression of MUC1 and 
nuclear grade. (TABLE 47 & CHART 20) 
 
TABLE  48 :CORRELATION OF AGE WITH MUC1  
EXPRESSION IN RCC 
AGE MUC1 POSITIVE 
MUC1 
NEGATIVE TOTAL 
<=50 19 3 22 
>50 16 2 18 
CHI-SQUARE 
TEST P value-0.810 40 
 
 In this study, 19 cases were positive for MUC1 in the age less than 
50 years. 16 cases were positive for MUC1 in the age more than 50 years. 
There is no correlation between age of presentation and MUC1 
expression. (TABLE 48) 
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TABLE  49 :CORRELATION OF SEX WITH MUC1  
EXPRESSION IN RCC 
SEX MUC1 POSITIVE 
MUC1 
NEGATIVE TOTAL 
Male 25 3 28 
Female 10 2 12 
CHI-SQUARE 
TEST P VALUE-0.602 40 
 
 In this study, 25 males were positive for MUC1. 10 females were 
positive for MUC1. There is no correlation between sex and MUC1 
expression. (TABLE 49) 
 
TABLE  50 :CORRELATION OF SIZE WITH MUC1  
EXPRESSION IN RCC 
SIZE MUC1 POSITIVE 
MUC1 
NEGATIVE TOTAL 
<=5 8 2 10 
>5 27 3 30 
CHI-SQUARE 
TEST P VALUE-0.408 40 
 
 In this study, 27 tumors positive for MUC1were more than 5 cm. 8 
tumors positive for MUC1were less than or equal to 5 cm. There is no 
correlation between size of tumor and MUC1 expression. (TABLE 50) 
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TABLE  51 :CORRELATION OF STAGE WITH MUC1  
EXPRESSION IN RCC 
STAGE MUC1 POSITIVE 
MUC1 
NEGATIVE TOTAL 
1 9 5 14 
2 9 0 9 
3 12 0 12 
4 5 0 5 
CHI-SQUARE 
TEST P VALUE -0.014 40 
 
 In this study, 9 stage 1 cases were positive for MUC1 and 5 cases 
were negative. In stage 2, 3 and 4, all cases were positive for MUC1. 
There is statistically significant correlation between stage at presentation 
and MUC1 expression. (TABLE 51) 
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DISCUSSION 
 
 Among urological malignancies, RCC is the most lethal 
malignancy. The incidence of RCC is increasing every year at a rate of 2 
to 4%.(3) One third of the patients present at the stage of metastasis. In 
patients with localised disease, surgery is thought to be curative but 30 to 
40 % of them develop metastasis during followup.(138)  This tumour is 
highly resistant to radiotheraphy and chemotheraphy.  
 
 Prognosis of this tumour is mainly dependant on nuclear grading 
and staging. It is not always possible to predict the prognosis with these 
factors.(5,9) RCC pathogenesis is not clear, behaviour and prognosis were 
difficult to be predicted. Postoperative treatment should be started at the 
most early in aggressive tumours to prevent metastasis.(132) 
 
 Cellular proliferation, apoptosis, metastatic spread are also 
predictive factors for biological and tumour progression.(6,8) Cellular 
proliferation rate is evaluated by using Ki67. Apoptosis degree in tumour 
can be measured by detecting mutated P53 antigen.(6)  Metastatic spread 
can be predicted by measuring the expression of MUC1 in RCC.(8) 
Combining the expression of P53, Ki67 and MUC1 with nuclear grade 
will be more effective  in predicting the prognosis of this tumour. 
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 In the present study, clinicopathological evaluation was done in 52 
cases of RCC. Immunohistochemical study was done for randomly 
selected 40 cases. An attempt was made to assess the significance of 
expression of P53, Ki67 and MUC1 in RCC cases. Correlation of 
expression of P53, Ki67 and MUC1 with nuclear grade was also made. 
  
 In this study, among 52 cases of renal cell carcinoma, maximum 36 
(69.23 %) cases were of clear cell RCC and 2nd maximum 7 (15.3 %)  
cases were of papillary RCC. Minimum cases of 2(3.8%) were of 
chromophobe RCC. This was found to be correlating with the following 
studies.  
 
TABLE 52: COMPARISON OF TYPES OF RENAL CELL 
CARCINOMA 
 
TYPES 
Ingrid 
Hodorov
aa et 
al(133) 
TimJ. 
Dudderid
ge et al(139) 
 
Petard 
et 
al(140) 
Zou H 
et 
al(141) 
 
Current 
study 
CLEAR CELL 
RCC 69% 66.5% 87.7% 67.5% 69.2% 
PAPILLARY 
RCC 11.9% 13% 9.7% 9.6% 15.3% 
CHROMOPHOBE 
RCC 7.1% 2.8% 2.5% 12.3% 3.8% 
RCC, 
UNCLASSIFIED 9.5% 15% - 1.8% 11.5% 
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 In all these studies, clear cell RCC is found to be the commonest 
type of RCC and the second commonest is papillary RCC.  
 
 In current study, the age of renal cell carcinoma patients  ranged 
from 27 years to 80 years with the mean age of 53 years. The highest 
incidence of renal cell carcinoma occurred in 41 to 50 year age group. 
This is in concurrence with the study done by Farahnaz  Noroozinia et 
al(137)  who observed a mean age of 56 ± 6 years with a range from 19 to 
86 years. 
 
TABLE 53: COMPARISON OF MEAN AGE OF  
RENAL CELL CARCINOMA 
 
MEAN AGE STUDIES 
56 ± 6yrs Farahnaz Noroozinia et al(137) 
58yrs(18-82) Robert et al(142) 
53 yrs(26-75) Sakineh Amouian et al(6) 
53 yrs(27-80) Current study 
 
 
 Also observed that 50% of renal cell carcinoma occurred in age 
less than or equal to 50 years. According to Pierre. I. Karakiewicz et 
al,(143) the risk of RCC-specific mortality was lowest among patients 
younger than 50 years.  Young patients are at  87% lower risk for RCC-
specific mortality  than those aged 50–75 years. The effect of age shows 
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prognostic significance; follow-up and secondary treatments should be 
adjusted according to the age of the patient.(143) 
 
 In the study done by Kyungeun Kim et al,(144)  age range in clear 
cell carcinoma is  28 to 86 years  and in current study,  age  range is 27-
77 years. In the study done by Xavier Leroy et al,(145) mean age in 
papillary RCC is 60 years (range, 27 to 81 y) and in current study, mean 
age is 52 yrs(range,38 -68y). 
 
 According to study done by N. K. Bhattacharyya et al,(146)  
incidence of renal cell carcinoma among males  was 73.3% and  females  
was 26.6% with a M:F ratio of 2.7:1. In concurrence with the above 
study, a significant male predominance who accounted for 73.1% of RCC 
cases and women accounted for 26.9%  was observed in current study. 
The male: female ratio observed in current study was 2.7:1. The similar 
sex distribution was observed in many studies. From all these studies 
males have increased risk of RCC when compared to females. 
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TABLE 54: COMPARISON OF SEX OF RENAL CELL 
CARCINOMA 
SEX 
N. K. 
Bhattacharyya et 
al(146) 
TimJ. 
Dudderidge et 
al(139) 
Current study 
Male 73.3% 68.2% 73.1% 
Female 26.6% 31.8% 26.9% 
Ratio 2.7:1 2.1:1% 2.7:1 
 
 Right sided tumors were more common than left sided tumors in 
current study and this is in concurrence with the study done by Devendar 
Katkooriet al.(147) There is  no significant difference between right and left 
side tumors in terms of  disease specific survival. 
 
TABLE 55: COMPARISON OF LATERALITY OF  
RENAL  CELL CARCINOMA 
STUDIES RIGHT SIDE LEFT SIDE BILATERAL
Ning Yi Yap et al(148) 48.3% 50% 0.7% 
DevendarKatkoori et 
al(147) 69% 31% - 
Current study 67% 33% - 
 
 In current study, 38(73.1%)  tumors were size more than 5 cm. 
14(26.9%) tumors were size less than equal to 5 cm. This was in 
concurrence with the study done by Farahnaz Noroozinia et al;(137)  in this 
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study among 64 cases,  48(75%)  tumors were size more than 5 cm. In 
both studies most of the tumors were more than 5 cm. 
 
 In this study of 52 cases median tumor diameter  is 7.5 cm. This is 
in concurrence with the study done by Lorenzo Tosco et al(149) where the 
median tumour diameter was 7.5 cm . In the study done by Jean-Jacques 
Patard et al,(150)  median tumour diameter was 6 cm. 
 
 In this study  4 cases showed ureter involvement and the 
percentage was 7.6%.according to  Farahnaz Noroozinia et al(137) 
percentage of ureter involvement was 6.3% . 
 
 In this study 10 cases showed renal vessel invasion and the 
percentage was 19.2%. This was in concurrence with  following studies. 
 
TABLE 56: COMPARISON OF RENAL VESSEL  INVASION OF 
RENAL  CELL CARCINOMA 
STUDIES PERCENTAGE OF  INVASION
Current study 19.2% 
Parekh DJ et al(151) 22% 
FarahnazNoroozinia et al(137) 12.5% 
 
  In this study, regional lymph nodal involvement present among 
4(7.7%) cases and this was not in concurrence with the following studies. 
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TABLE 57: COMPARISON OF LYMPH NODE INVOLVEMENT 
OF RENAL  CELL CARCINOMA 
STUDIES PERCENTAGE OF LYMPHNODE INVOLVEMENT 
Chunwoo Lee et al(152) 4% 
Giacomo Novara et al(153) 4% 
K Fujita et al(136) 17.7% 
Current study 7.7% 
 
 
 Among the 52 cases of renal cell carcinoma, distant metastasis 
present among 3(5.8%). In all following studies distant metastasis was 
found to be less than 10%. 
 
TABLE 58: COMPARISON OF METASTASIS OF  
RENAL  CELL CARCINOMA 
STUDIES PERCENTAGE OF METASTASIS 
Current study 5.8% 
Alexander Laird et al(138) 7.1% 
Chunwoo Lee et al(152) 8.5% 
Giacomo Novara et al(153) 6% 
 
 Among the 52 cases of renal cell carcinoma, maximum cases were 
presented at T1 stage and 2nd maximum cases were presented at  T3 
stage. Minimum cases were presented at T4 stage. This was correlating 
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with the study done by Chunwoo Lee et al.(152)   In the study done by 
Lorenzo Tosco et al,(149)  T3 is the most common stage of presentation. 
 
TABLE 59: COMPARISON OF T stage AT PRESENTATION IN 
RENAL  CELL CARCINOMA 
T stage at 
presentation 
Lorenzo 
Tosco et 
al(149) 
Current study Chunwoo Lee et al(152) 
T1 25 ( 23%) 18(34.6%) 71% 
T2 24  (22%) 13(25%) 12.5% 
T3 46  (42.2%) 15(28.8%) 15.5% 
T4 14( 12.8%) 6(11.5%) 1.8% 
Total 109 52  
 
 In this study most of the clear cell RCC were T1 stage at 
presentation and least stage of presentation was T4 stage. This was in 
concurrence with the study done by   Thomas Weber et al.(154) 
 
 In several studies stage1is the common stage of presentation and 
stage 4 is the least common stage of presentation which was in 
concurrence with this study. 
 
 In this study among the 52 cases of renal cell carcinoma, maximum 
17(32.7%) cases were of grade 3 and 2nd maximum 16(30.8 %) cases 
were of grade 2. This was correlating with the study done by 
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N.K.Bhattacharyyaet al,(146) in which maximum cases were of grade 3 and 
grade 2. 
 
TABLE 60 : COMPARISON OF NUCLEAR GRADE OF  
RENAL  CELL CARCINOMA 
Nuclear 
grade 
Sakineh 
Amouian 
et al(6) 
N.K.Bhattacharyya
et al (146) 
Jean-
Jacques 
Patard et 
al(150) 
Current 
study 
G1 30% 10% 20.5% 17.3% 
G2 43% 36.6% 36.7% 30.8% 
G3 16.9% 36.6% 34.4% 32.7% 
G4 10% 16.6% 8.4% 19.2% 
 
 In this study, most of the clear cell RCC cases were seen in in 
grade 2 and 3. This was correlating with the study done by N. K. 
Bhattacharyya et al.(146) Most of the papillary RCC were of grade 2. This 
was correlating with the study done by Xavier Leroy et al.(145) 
 
KI67 
 In this study, 72.5% of tumors were positive for ki67. In the study 
done by Sakineh Amouian et al,(6) out of 30 tumor studied, 20(66.6%) 
were positive for ki67. In the study done by Brett Delahunt et al,(155)206 
cases were studied and ki67  expression was detected in  83%.  In 1239 
cases studied by Kai Zheng et al,(132), ki67 was detected in 47.7%. 
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TABLE 61: COMPARISON OF KI67 POSITIVITY OF  
RENAL  CELL CARCINOMA 
STUDIES PERCENTAGE OF KI67 POSITIVITY 
SakinehAmouian et al(6) 66.6% 
Brett Delahunt et al(155) 83% 
Kai Zheng et al(132) 47.7% 
Current study 72.5% 
 
 In grade 1 tumours, range of ki67 labelling index was 2-14%. In 
grade 2, range of ki 67 labelling index was 4-36%. This was in 
concurrence with the study done by Brett Delahunt et al.(155) 
 
 In this study, range of ki67 labelling index in clear cell RCC was 0 
to 69%.This is in concurrence with the study  done by  Matthew H. T. Bui 
et al;(156)  in his study,  Ki67 labelling ranged from 0% to 60% and upto 
64% in the study done by Wafaa Helmy et al(7). 
 
 In high grade tumors of clear cell RCC, ki67 labelling index was 
30-69%. This was concurrence with the study done by Wafaa Helmy et 
al.(7) 
 
 In this study there is an increase in proliferative index of ki67 with 
increase in nuclear grade. This was similar to the studies done by Peter K 
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Wong et al,(157)Matthew H. T. Bui et al,(156)Kai Zheng et al,(132) Sakineh 
Amouian et al,(6) Arnold B. Gelb et al.(158) 
 
 There is no significant correlation between ki67 expression and 
tumor types. This was similar to the study conducted by Peter K.  
Wong et al.(157) 
 
 In current study, size  of the tumor failed to show a correlation with 
Ki-67. This was in concurrence with the study done by Peter K. Wong  
et al.(157) 
 
 In the study done by Minna Kankuri et al,(134) Ki67 expression was  
correlated with stage .This was in concurrence with this study. 
 
P53 
 In this study, 25% of cases were positive for p53 expression. In the 
study done by Farahnaz Noroozinia et al,(137)  thirteen of 64 (20.3%) cases  
were P53 positive.  In the study done by Sakineh Amouian et al,(6) 13 out 
of 30 tumors(  43.3%) were positive for p53. There is variable expression 
of p53 in different studies. 
 
 In the study done by Ingrid Hodorovaa et al(133) and  Farahnaz 
Noroozinia et al,(137)  p53 expression was found to be  higher in other 
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types of RCC than in the clear cell type of RCC; similar findings were 
also observed in current study. 
 
 Papillary RCC has high p53 expression when compared to clear 
cell RCC. This was correlating with the study done by Farahnaz 
Noroozinia et al;(137) in their study, 94.8% of clear cell RCC were 
negative for p53 and 53.8%  of papillary RCC were positive for p53 and 
their study has a positive correlation between p53 expression and 
histological type with a p value of <0.05 which was similar to the finding 
observed in the current study. 
 
 In this study 20 (50%) of RCC cases were not immunoreactive for 
p53.25% of RCC expressed p53 in the range of 1-10%. Maximum 
expression of  p53 was seen in 2.5% of cases. In the study done by Ingrid 
Hodorovaa et al,(135) 42 RCC cases were studied and 66% were not 
immunoreactive for p53 and 19% of RCC expressed p53 in the range of 
1-10% and maximum expression  of p53 was seen in 4.7% of cases. 
The expression of p53 with nuclear grade in current study is found to 
correlate with the study done by Farahnaz Noroozinia et al.(137)  In both 
the studies there is no correlation between p53 expression and nuclear 
grade. 
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TABLE 62: COMPARISON OF P53 EXPRESSION WITH 
NUCLEAR GRADING OF RENAL  CELL CARCINOMA 
 
Farahnaz Noroozinia et al(137) CURRENT STUDY 
Nuclear 
grade P53 positive P53 negative P53 positive 
P53 
negative 
Grade1 0 100% 0 100% 
Grade2 26% 74% 27% 73% 
Grade3 25% 75% 25% 75% 
Grade4 0 0 40% 60% 
P value 0.1 0.3 
 
 In current study, there is no correlation between age, gender, size 
with P53 expression. This is in concurrence with the study done by 
Farahnaz Noroozinia et al.(137) 
 
MUC1 
 In this study more than 90% of cases  of RCC cases were 
immunoreactive for MUC1 and this is in concurrence with  the study 
done by Cord Langner et  al.(135) 
 
 In this study 85%cases of clear cell RCC were positive for MUC1 
expression. In the study done by Xavier Leroy et al(8) MUC1 expression 
was found in all Clear cell RCCs. 
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 In papillary RCC, out of 7 cases, 6 were positive for MUC1 
expression. The cases which are positive are all type 1 tumors and only 
one type 2 tumor studied which was negative for MUC1.  This was in 
concurrence with the study done by cord langner et al.(135)In his study in  
papillary carcinomas, MUC1 immunoreactivity was found in 12/12 
(100%) type 1 tumours and also in concurrence with study done by 
Xavier Leroy et al.(145) 
 
 In this study, all 2 chromophobe cases showed positive MUC1 
expression; in the study done by cord langner et al,(135) 20/22(91%) 
showed positivity. 
 
 In all the types of RCC, expression of MUC1 was more than 50% 
in current study. This was in correlation with the study  done by Cord 
Langner et al;(135) in their study, MUC1 immunoreactivity of more than 
50% of tumor cells was found in 68/133 (51%) conventional, 15/22 
(68%) chromophobe, and 11/20 (55%) papillary RCC. 
 
 According to study done by K Fujita et al,(136) 51 cases of RCC 
were studied for MUC1 expression. In their study, K Fujita et al(136) 
observed a positive correlation of nuclear grade  with MUC1 expression 
with a p value of <0.05 which found to be correlated with current study 
with a p value of 0.02. 
  
 
SUMMARY 
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SUMMARY 
 
 From august 2011 to august 2013, a total of 31,237 specimens were 
received for histopathological examination in the institute of 
pathology, Madras  Medical College.  
 Among this, 52 were nephrectomy specimens done for RCC. 
  Of this, 36 were clear cell RCC, 8 were papillary RCC, 2 were 
Chromophobe RCC, 6 were unclassified RCC. 
  Clear cell RCC was the most common histological type.  
 Most common nuclear grade was grade 3 (32.8%) followed by grade 2 
(32.7%). 
 The mean age of Renal cell carcinoma in this study was 53 years. 
 The youngest age of presentation was 27 years and the oldest age of 
presentation was 80 years. 
 The incidence of RCC was comparatively higher  in the age group of 
41-50 years. 
  In this study there was an overall male preponderance. 
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 Right sided tumors were more common than left sided tumors 
accounting for 67.31%. 
 The maximum dimension of most of the RCC were more than 5 cm 
(38 cases, 73.1%).  
 The median diameter of the tumor is 7.5 cm. 
 Capsular infiltration was present in 32.7%. 
 Perinephric tissue involvement  was present in 25%. 
 Gerota’s fascia involvement was present in 9.6% 
 Ureter invasion was present in 7.7%. 
  Renal vessel invasion was present in 19.2%. 
 Adrenal involvement was present in 7.7%. 
 7.7% of the patients had regional lymphnodal involvement. 
 5.8% of the patients had distant metastasis at the time of presentation. 
 Maximum cases of renal cell carcinoma presented in T1bstage 
(21.6%) and T3a stage (21.6%). 
 Most common stage at the time of diagnosis was stage 1(34.6%) 
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 Among the total 40 cases, 29 cases showed positivity for KI67, 
accounting for 72.5%. 
  No statistical significance was found between the histological type 
and KI67 expression. 
 KI67 expression was high in nuclear grade 4 tumors (9 cases,90%) 
  The  association was found to be statistically significant between 
nuclear grade and KI67 expression 
 Nuclear grade 3 tumors had high  KI67 labeling  index and the mean 
LI was 36.9% for grade 3 tumors. 
 No statistical significance was found between the age and KI67 
expression. 
  The association between sex and KI67 expression was not statistically 
significant. 
 The association between size of the tumor and KI67 expression was 
not statistically significant. 
 The  association was found to be statistically significant between stage 
and KI67 expression. 
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 Among the total 40 cases, 10 cases showed positivity for P53, 
accounting for 25%. 
 2.5% of cases had high level of P53 expression. 
 The  association was found to be statistically significant between 
histological type of the tumor and P53 expression. 
 No statistical significance was found between nuclear grade and P53 
expression. 
 No statistical significance was found between age and P53 expression. 
 The association between sex and P53 expression was not statistically 
significant. 
 The association between size of the tumor and P53 expression was not 
statistically significant. 
 The association between stage at presentation and P53 expression was 
not statistically significant. 
 Among the total 40 cases, 35 cases showed positivity for MUC1, 
accounting for 87.5%. 
 Maximum cases (13 cases,32.5% ) had MUC1expression in the range 
of 75-90%. 
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 The association between histological type and MUC1 expression was 
not statistically significant. 
 All  grade 4 tumors had more than 75% MUC1 expression. 
 The  association was found to be statistically significant between 
nuclear grade and MUC1 expression. 
 No statistical significance was found between age and MUC1 
expression. 
 No statistical significance was found between sex and MUC1 
expression. 
 No statistical significance was found between size of the tumor and 
MUC1 expression. 
 The  association was found to be statistically significant between stage 
at presentation and MUC1 expression. 
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CONCLUSION 
 
 This study was hospital-based and may not represent the true 
incidence of the disease in the community.  52 cases  of Renal Cell 
Carcinoma were studied in the Institute of Pathology from  august 2011 
to august 2014. The mean age of  occurrence of  RCC is 53 years with 
predominance in males. The most common histological type noted was 
clear cell RCC, with majority of the cases exhibiting nuclear grade 3. 
 
 There is association of ki67 expression with nuclear grade and 
stage. There is no correlation between P53 and nuclear grade. The 
expression of P53 is found to be associated with histological types. There 
is association of MUC1 expression with nuclear grade and stage.  
 
 The combined detection of p53, Ki67, MUC1 expressions, which 
are superior to single marker along with nuclear grade and stage, could be 
used to significantly improve the accuracy in predicting the prognosis of 
RCC patients. 
  
 
ANNEXURES 
 
 
ANNEXURE – I 
 
PROFORMA  
 
Case number :                                                                          Name :  
 
HPE number :                                                                            Age :  
 
IP number :                                                                                 Sex :  
 
Clinical history :  
 
Clinical diagnosis :  
 
Imaging :  
 
Type of procedure done: 
 
Nature of specimen :  
 
  
GROSS  
  
Tumour location :  
 
Tumour size :  
 
Tumour configuration :                                               capsular infiltration:  
 
Renal pelvis:                                                                 perinephric tissue: 
 
Renal vessels:                                                               Gerota’s  fascia: 
 
Ureter:                                                                           Adjacent kidney : 
 
Adrenal gland:  
 
Lymph Nodes  :  
 
MICROSCOPY  
 
Histological type : Furhman nuclear grade : G1 / G2 / G3 / G4 
 
Renal pelvis: 
 
Capsular infiltration: present/ absent 
 
Perinephric tissue: free/ involved 
 
Gerota’s fascia: free/ involved 
 
Renal artery invasion: present/ absent 
 
Renal vein invasion: present/ absent 
 
Ureter : free/ involved 
 
Adrenal: free/ involved 
 
Lymph nodes-total nodes dissected and number of nodes involved 
 
Distant metastasis :  
 
TNM staging :  
 
 
IMMUNOHISTOCHEMISTRY  
 
Ki67 : positive /negative  
% of tumour nuclei showing reaction  
 
P53:  positive /negative 
% of tumour nuclei showing reaction and grade 
 
MUC1: positive /negative 
% of tumour cells showing membranous/cytoplasmic positivity and grade 
 
 
 
 
 
 
 
ANNEXURE – II 
 
 WHO histological classification of tumours of the kidney 
Renal Cell Tumors 
Clear cell renal cell carcinoma 
Multilocular clear cell renal cell carcinoma  
Papillary renal cell carcinoma  
Chromophobe renal cell carcinoma  
Carcinoma of the collecting ducts of Bellini  
Renal medullary carcinoma  
Xp11 translocation carcinomas 
Carcinoma associated with neuroblastoma 
Mucinous tubular and spindle cell carcinoma 
Renal cell carcinoma, unclassified 
Papillary adenoma  
Oncocytoma  
Metanephric tumours 
Metanephric adenoma  
Metanephric adenofibroma  
Metanephric stromal tumour 
Nephroblastic tumours 
Nephrogenic rests 
Nephroblastoma  
Cystic partially differentiated nephroblastoma  
Mesenchymal tumours 
Occurring Mainly in Children 
           Clear cell sarcoma  
           Rhabdoid tumour  
           Congenital mesoblastic nephroma  
           Ossifying renal tumour of infants  
Occurring Mainly in Adults 
          Leiomyosarcoma (including renal vein)  
          Angiosarcoma  
          Rhabdomyosarcoma  
          Malignant fibrous histiocytoma   
          Haemangiopericytoma 
          Osteosarcoma  
          Angiomyolipoma  
           Epithelioid angiomyolipoma 
           Leiomyoma  
           Haemangioma  
           Lymphangioma  
           Juxtaglomerular cell tumour  
           Renomedullary interstitial cell tumour  
          Schwannoma  
          Solitary fibrous tumour  
Mixed mesenchymal and epithelial tumours 
Cystic nephroma  
Mixed epithelial and stromal tumour 
Synovial sarcoma  
Neuroendocrine tumours 
Carcinoid  
Neuroendocrine carcinoma  
Primitive neuroectodermal tumour  
Neuroblastoma  
Phaeochromocytoma  
Haematopoietic and lymphoid tumours 
Lymphoma 
Leukaemia 
Plasmacytoma  
Germ cell tumours 
Teratoma  
Choriocarcinoma  
Metastatic tumors                                                   
                             
       
ANNEXURE – III 
                  TNM classification of renal cell carcinoma 
 
T – Primary Tumour 
TX- Primary tumour cannot be assessed 
T0 -No evidence of primary tumour 
T1 -Tumour 7 cm or less in greatest dimension, limited to the                                        
kidney 
T1a- Tumour 4 cm or less in greatest dimension, limited to the kidney 
T1b -Tumour more than 4 cm but not more than 7 cm in greatest 
dimension, limited to the kidney 
T2 - Tumour more than 7 cm in greatest dimension, limited to the kidney 
T2 a - Tumour more than 7 cm but less than 10 cm  in greatest dimension, 
limited to the kidney  
T2 b - Tumour more than 10 cm in greatest dimension, limited to the 
kidney 
T3 - Tumour extends into major veins or  perinephric tissues but not into 
adrenal gland  and not beyond Gerota fascia 
T3a - Tumour grossly extends into the renal vein or its segmental (muscle 
containing) branches, or tumor invades perirenal and/or renal sinus fat but 
not beyond Gerota’s fascia. 
T3b - Tumour grossly extends into  vena cava  below diaphragm 
T3c - Tumour grossly extends into vena cava or its wall above diaphragm 
T4 - Tumour directly invades beyond Gerota fascia(including contiguous 
extension into the ipsilateral adrenal gland) 
 N – Regional Lymph Nodes 
NX - Regional lymph nodes cannot be assessed 
N0 - No regional lymph node metastasis 
N1-  Metastasis in regional lymph node 
M – Distant Metastasis 
MX - Distant metastasis cannot be assessed 
M0 - No distant metastasis 
M1 - Distant metastasis 
Anatomic Stage/ prognostic groups 
Stage I    T1 N0 M0 
Stage II  T2 N0 M0 
Stage III  T3 N0 M0 
   T1, T2, T3 N1 M0 
Stage IV  T4 N0, N1 M0 
                              Any T Any N M1 
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1. HPE NO - HISTOPATHOLOGICAL EXAMINATION  
    NUMBER 
2. M    - MALE 
3. F   - FEMALE 
4. R    - RIGHT 
5. L  - LEFT 
6. P  - PRESENT 
7.  A  - ABSENT 
8. CI  - CAPSULAR INFILTRATION 
9. PI  - PERINEPHRIC TISSUE INVOLVEMENT 
10. GF  - GEROTA’S FASCIA INVOLVEMENT 
11. UR  - URETER INVASION 
12. RV  - RENAL VEIN INVASION 
13. RA  - RENAL ARTERY INVASION 
14. AI  - ADRENAL INVOLVMENT 
15. LN  - LYMPH NODE INVOLVEMENT 
16. MT  - METASTASIS 
17. ST  - STAGE 
18. HT  - HISTOLOGICAL TYPE 
 1  -  CLEAR CELL RCC 
 2  -  PAPILLARY RCC 
 3  -  CHROMOPHOBE RCC 
        4  -  UNCLASSIFIED RCC 
19. NG  - NUCLEAR GRADE 
20. LI  - LABELLING INDEX 
21. POS  - POSITIVE 
22. NEG  - NEGATIVE 
23. P53 G  - P53 GRADE 
24. MUC1 G - MUC1 GRADE 
 
